<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topical treatment for facial burns - Hoogewerf, CJ - 2020 | Cochrane Library</title> <meta content="Topical treatment for facial burns - Hoogewerf, CJ - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008058.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topical treatment for facial burns - Hoogewerf, CJ - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008058.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008058.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Topical treatment for facial burns" name="citation_title"/> <meta content="Cornelis J Hoogewerf" name="citation_author"/> <meta content="Dutch Burns Foundation" name="citation_author_institution"/> <meta content="M Jenda Hop" name="citation_author"/> <meta content="Association of Dutch Burn Centres" name="citation_author_institution"/> <meta content="Marianne K Nieuwenhuis" name="citation_author"/> <meta content="Association of Dutch Burn Centres" name="citation_author_institution"/> <meta content="Irma MMH Oen" name="citation_author"/> <meta content="Association of Dutch Burn Centres" name="citation_author_institution"/> <meta content="Esther Middelkoop" name="citation_author"/> <meta content="Amsterdam Movement Sciences and Association of Dutch Burn Centers, Red Cross Hospital" name="citation_author_institution"/> <meta content="Margriet E Van Baar" name="citation_author"/> <meta content="Association of Dutch Burn Centres" name="citation_author_institution"/> <meta content="baarm@maasstadziekenhuis.nl" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD008058.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/07/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008058.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008058.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008058.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Topical; Anti-Infective Agents [administration &amp; dosage, *therapeutic use]; Bias; Burns [*therapy]; Carboxymethylcellulose Sodium [administration &amp; dosage, therapeutic use]; Facial Injuries [*therapy]; Randomized Controlled Trials as Topic; *Skin, Artificial; Wound Healing [drug effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008058.pub3&amp;doi=10.1002/14651858.CD008058.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="23LRTUA6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008058\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008058\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008058.pub3",title:"Topical treatment for facial burns",firstPublishedDate:"Jul 29, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Wounds Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008058.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008058.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008058.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008058.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008058.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008058.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008058.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008058.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008058.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008058.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11176 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008058.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-sec-0129"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-sec-0019"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-sec-0020"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-sec-0115"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/appendices#CD008058-sec-0134"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/supinfo/CD008058StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/supinfo/CD008058StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topical treatment for facial burns</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/information#CD008058-cr-0004">Cornelis J Hoogewerf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/information#CD008058-cr-0005">M Jenda Hop</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/information#CD008058-cr-0006">Marianne K Nieuwenhuis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/information#CD008058-cr-0007">Irma MMH Oen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/information#CD008058-cr-0008">Esther Middelkoop</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008058.pub3/information#CD008058-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Margriet E Van Baar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/information/en#CD008058-sec-0166">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 July 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008058.pub3">https://doi.org/10.1002/14651858.CD008058.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008058-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008058-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008058-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008058-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008058-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD008058-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008058-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008058-abs-0001" lang="en"> <section id="CD008058-sec-0001"> <h3 class="title" id="CD008058-sec-0001">Background</h3> <p>Burn injuries are an important health problem. They occur frequently in the head and neck region. The face is the area central to a person's identity that provides our most expressive means of communication. Topical interventions are currently the cornerstone of treatment of burns to the face. </p> </section> <section id="CD008058-sec-0002"> <h3 class="title" id="CD008058-sec-0002">Objectives</h3> <p>To assess the effects of topical interventions on wound healing in people with facial burns of any depth. </p> </section> <section id="CD008058-sec-0003"> <h3 class="title" id="CD008058-sec-0003">Search methods</h3> <p>In December 2019 we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE (including In‐Process &amp; Other Non‐Indexed Citations); Ovid Embase and EBSCO CINAHL Plus. We also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as reviews, meta‐analyses and health technology reports to identify additional studies. There were no restrictions with respect to language, date of publication or study setting. </p> </section> <section id="CD008058-sec-0004"> <h3 class="title" id="CD008058-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) that evaluated the effects of topical treatment for facial burns were eligible for inclusion in this review. </p> </section> <section id="CD008058-sec-0005"> <h3 class="title" id="CD008058-sec-0005">Data collection and analysis</h3> <p>Two review authors independently performed study selection, data extraction, risk of bias assessment and GRADE assessment of the certainty of the evidence. </p> </section> <section id="CD008058-sec-0006"> <h3 class="title" id="CD008058-sec-0006">Main results</h3> <p>In this first update, we included 12 RCTs, comprising 507 participants.</p> <p>Most trials included adults admitted to specialised burn centres after recent burn injuries. </p> <p>Topical agents included antimicrobial agents (silver sulphadiazine (SSD), Aquacel‐Ag, cerium‐sulphadiazine, gentamicin cream, mafenide acetate cream, bacitracin), non‐antimicrobial agents (Moist Exposed Burn Ointment (MEBO), saline‐soaked dressings, skin substitutes (including bioengineered skin substitute (TransCyte), allograft, and xenograft (porcine Xenoderm), and miscellaneous treatments (growth hormone therapy, recombinant human granulocyte‐macrophage colony‐stimulating factor hydrogel (rhGMCS)), enzymatic debridement, and cream with Helix Aspersa extract). </p> <p>Almost all the evidence included in this review was assessed as low or very low‐certainty, often because of high risk of bias due to unclear randomisation procedures (i.e. sequence generation and allocation concealment); lack of blinding of participants, providers and sometimes outcome assessors; and imprecision resulting from few participants, low event rates or both, often in single studies. </p> <p><b>Topical antimicrobial agents versus topical non‐antimicrobial agents</b> </p> <p>There is moderate‐certainty evidence that there is probably little or no difference between antimicrobial agents and non‐antimicrobial agents (SSD and MEBO) in time to complete wound healing (hazard ratio (HR) 0.84 (95% confidence interval (CI) 0.78 to 1.85, 1 study, 39 participants). Topical antimicrobial agents may make little or no difference to the proportion of wounds completely healed compared with topical non‐antimicrobial agents (comparison SSD and MEBO, risk ratio (RR) 0.94, 95% CI 0.68 to 1.29; 1 study, 39 participants; low‐certainty evidence). We are uncertain whether there is a difference in wound infection (comparison topical antimicrobial agent (Aquacel‐Ag) and MEBO; RR 0.38, 95% CI 0.12 to 1.21; 1 study, 40 participants; very low‐certainty evidence). No trials reported change in wound surface area over time or partial wound healing. There is low‐certainty evidence for the secondary outcomes scar quality and patient satisfaction. Two studies assessed pain but it was incompletely reported. </p> <p><b>Topical antimicrobial agents versus other topical antimicrobial agents</b> </p> <p>It is uncertain whether topical antimicrobial agents make any difference in effects as the evidence is low to very low‐certainty. For primary outcomes, there is low‐certainty evidence for time to partial (i.e. greater than 90%) wound healing (comparison SSD versus cerium SSD: mean difference (MD) –7.10 days, 95% CI –16.43 to 2.23; 1 study, 142 participants). There is very low‐certainty evidence regarding whether topical antimicrobial agents make a difference to wound infection (RR 0.73, 95% CI 0.46 to 1.17; 1 study, 15 participants). There is low to very low‐certainty evidence for the proportion of facial burns requiring surgery, pain, scar quality, adverse effects and length of hospital stay. </p> <p><b>Skin substitutes versus topical antimicrobial agents</b> </p> <p>There is low‐certainty evidence that a skin substitute may slightly reduce time to partial (i.e. greater than 90%) wound healing, compared with a non‐specified antibacterial agent (MD –6.00 days, 95% CI –8.69 to –3.31; 1 study, 34 participants). </p> <p>We are uncertain whether skin substitutes in general make any other difference in effects as the evidence is very low certainty. Outcomes included wound infection, pain, scar quality, adverse effects of treatment and length of hospital stay. </p> <p>Single studies showed contrasting low‐certainty evidence. A bioengineered skin substitute may slightly reduce procedural pain (MD –4.00, 95% CI –5.05 to –2.95; 34 participants) and background pain (MD –2.00, 95% CI –3.05 to –0.95; 34 participants) compared with an unspecified antimicrobial agent. In contrast, a biological dressing (porcine Xenoderm) might slightly increase pain in superficial burns (MD 1.20, 95% CI 0.65 to 1.75; 15 participants (30 wounds)) as well as deep partial thickness burns (MD 3.00, 95% CI 2.34 to 3.66; 10 participants (20 wounds)), compared with antimicrobial agents (Physiotulle Ag (Coloplast)). </p> <p><b>Miscellaneous treatments versus miscellaneous treatments</b> </p> <p>Single studies show low to very low‐certainty effects of interventions. Low‐certainty evidence shows that MEBO may slightly reduce time to complete wound healing compared with saline soaked dressing (MD –1.7 days, 95% CI –3.32 to –0.08; 40 participants). In addition, a cream containing Helix Aspersa may slightly increase the proportion of wounds completely healed at 14 days compared with MEBO (RR 4.77, 95% CI 1.87 to 12.15; 43 participants). We are uncertain whether any miscellaneous treatment in the included studies makes a difference in effects for the outcomes wound infection, scar quality, pain and patient satisfaction as the evidence is low to very low‐certainty. </p> </section> <section id="CD008058-sec-0007"> <h3 class="title" id="CD008058-sec-0007">Authors' conclusions</h3> <p>There is mainly low to very low‐certainty evidence on the effects of any topical intervention on wound healing in people with facial burns. The number of RCTs in burn care is growing, but the body of evidence is still hampered due to an insufficient number of studies that follow appropriate evidence‐based standards of conducting and reporting RCTs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008058-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008058-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008058-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008058-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008058-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008058-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008058-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008058-abs-0015">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008058-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD008058-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008058-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008058-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008058-abs-0002" lang="en"> <h3>Topical treatment for facial burns</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effects of topical (applied to the surface of the skin) treatments for healing burn wounds on the face or neck. We wanted to find out which treatments were most effective at healing these wounds and improving the appearance of scars, which is a particularly important issue in relation to facial burn injuries. We also wanted to find out how topical treatments affected the risk of complications such as infection and pain, and how they impacted on peoples' quality of life. </p> <p><b>Background</b> </p> <p>Burn injuries are an important health problem, and a major global cause of disability and disfigurement in both adults and children. Women and children in low‐income countries are at particular risk. Burns pose particular problems when they occur on the head or neck. The face is central to a person's identity and plays a vital role in communication. Other basic functions such as hearing, smell and breathing may become affected as a direct result of a facial burn. Topical treatments such as (non) antimicrobial creams and skin substitutes, are most commonly used to treat facial burns. We wanted to compare the effectiveness of these treatments to evaluate their benefits and harms. </p> <p><b>Study characteristics</b> </p> <p>In December 2019, we searched for randomised controlled trials (RCTs) investigating topical treatments for facial burns. RCTs are medical studies where the treatment or care people receive is chosen at random. This type of study design provides the most reliable health evidence about whether different approaches to treatment or care can make a difference. We found 12 studies that were suitable for inclusion in this review update, with 507 participants with mean ages ranging from 5.3 to 41.9 years. Three studies compared antimicrobials with non‐antimicrobials agents, two studies compared different antimicrobials, four studies compared skin substitutes with antimicrobials, while four studies compared a variety of topical treatments. One study contributed to two comparisons. Eight studies were small (fewer than 40 participants) and almost all studies were at high risk of bias due to lack of blinding (where participants and evaluators may have known which group the participants were allocated to and interpreted effects differently). </p> <p><b>Key results</b> </p> <p>Overall, there is mainly low to very low‐certainty evidence on the effects of any topical intervention on wound healing or infection in people with facial burns. In addition, there is low to very low‐certainty evidence on the effects of the included interventions on need for surgery, pain, scar quality, patient satisfaction, length of hospital stay and side effects. </p> <p>All results were at high risk of bias and varied, which may have exaggerated the effects.</p> <p><b>Certainty of the evidence</b> </p> <p>Overall, the certainty of the evidence about the effectiveness of topical treatments for facial burns is low to very low. There is insufficient reliable evidence as to whether topical treatments improve outcomes for people with facial burns including improving wound healing, or rates of infection. Better trial design and reporting of these studies is required to contribute to evidence‐based burn care. </p> <p><b>How up to date is this review?</b> </p> <p>We searched for studies that had been published up to December 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008058-sec-0129" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008058-sec-0129"></div> <h3 class="title" id="CD008058-sec-0130">Implications for practice</h3> <section id="CD008058-sec-0130"> <p>There is mainly low or very low‐certainty evidence on the effects of any topical intervention on wound healing in people with facial burns. This means that we do not know with certainty whether topical agents improve outcomes in people with facial burns. The number of randomised controlled trials (RCT) in burn care is growing, but the body of evidence is still hampered by an insufficient number of studies that follow appropriate evidence‐based standards of conducting and reporting RCTs. In the absence of evidence on the effects of topical treatments in facial burns, patient satisfaction or patient comfort should probably guide treatment decisions. One can assume that treatments with lower number of wound dressings procedures and a shorter time to discharge, probably contribute to improved quality of care, if all other effects are similar. </p> </section> <h3 class="title" id="CD008058-sec-0131">Implications for research</h3> <section id="CD008058-sec-0131"> <p>The substantial increase in the number of included RCTs did not result in high‐certainty evidence for the included comparisons. The RCTs added in the update had similar high risks of bias as the studies included in the original review. In addition, most newly included RCTs lacked precision, because of small sample sizes and low event rates. In order to improve the certainty of the evidence, future studies should be designed in conjunction with a trials expert and a statistician and include a sample size calculation. An appropriate sequence generation and allocation concealment should be used in order to reduce risk of bias, and blinding should be attempted. Although it is difficult to blind participants and care providers, it is possible to blind outcome assessors. A sample size calculation should be used in order to increase statistical power and give a more precise overall estimate of effect size. Furthermore, future trialists might add patient satisfaction and quality of life to their outcomes of interest, as these outcomes are especially important for patients. In addition, future trialists might give some extra thought to the outcome wound healing, as this outcome can be reported in numerous ways and it is not always analysed correctly (i.e. survival analyses). Ideally, all trialists should use the same measurement for wound healing, and as a result, allow comparisons to be made. We suggest a clinical important measurement, for instance time to 95% wound healing, that could be considered as the percentage of wound healing necessary for discharge to outpatient management. This subjective wound assessment, performed by an experienced observer, is found to be a reliable (<a href="./references#CD008058-bbs2-0037" title="BloemenMC , Van ZuijlenPP , MiddelkoopE . Reliability of subjective wound assessment. Burns2011;37(4):566-71.">Bloemen 2011</a>) and valid tool (<a href="./references#CD008058-bbs2-0038" title="BloemenMC , BoekemaBK , VligM , Van ZuijlenPP , MiddelkoopE . Digital image analysis versus clinical assessment of wound epithelialization: a validation study. Burns2012;38(4):501-5.">Bloemen 2012</a>). Topical interventions are numerous, so future research should focus on those interventions most likely to benefit patients. Special attention should be given to wound dressings without daily wound care sessions; these are likely to contribute highly to patient comfort and patient satisfaction. </p> <p>In addition to improvements in the design and conduct of studies, the standard of reporting on trials should be improved as well. The CONSORT standards of reporting on RCTs should be followed. The guidelines for reporting on RCTs in wound care are a helpful additional tool for optimal generation of evidence in this field (<a href="./references#CD008058-bbs2-0039" title="BrölmannFE , EskesAM , SumpioBE , MayerDO , MooreZ , AgrenMS , et al. Fundamentals of randomized clinical trials in wound care: reporting standards. Wound Repair and Regeneration2013;21(5):641-7. [DOI: 10.1111/wrr.12087]">Brölmann 2013</a>). The Cochrane Reviews to date show that evidence is emerging, although it takes substantial time and effort. </p> <p>We categorised the topical treatments in four categories focusing on both antimicrobial function and type of dressing (i.e. skin substitutes). In future studies, probably the main focus should be on the comparisons of topical intervention with and without daily wound care. This focus should be combined with patient satisfaction or patient comfort as a major outcome. Such a study would provide highly relevant information from the patients' perspectives. Our review found mostly low to very low‐certainty evidence on the effects of any topical intervention so it is possible that wound dressings and skin substitutes have similar time to wound healing and infection, compared with other topical agents. However, these interventions could potentially contribute to patient comfort because of the lower number of wound dressing sessions and probably shorter time to discharge with these treatments. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008058-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008058-sec-0008"></div> <div class="table" id="CD008058-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Topical antimicrobial agent compared with topical non‐antimicrobial agent for facial burns</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p><b>Topical antimicrobial agent compared with topical non‐antimicrobial agent for facial burns</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with facial burns </p> <p><b>Setting:</b> burn centres </p> <p><b>Intervention:</b> topical antimicrobial agent </p> <p><b>Comparison:</b> topical non‐antimicrobial agent </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> <p><b>(follow‐up)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with topical non‐antimicrobial agent</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with topical antimicrobial agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Time to complete wound healing</b> (time to event data) </p> <p>(6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported HR (adjusted for total body surface area burned) was 0.84 (0.78 to 1.85) (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Facial burns treated with SSD probably have a similar time to complete wound healing, compared with MEBO. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete wound healing</b> (days) </p> <p>(until wound healing)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean time to wound healing 10.35 (SD 2.8) and 12.05 (SD 2.4) (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to wound healing</p> <p>10.05 (SD 2.3) (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in time to wound healing between topical anti‐microbial agents (Aquacel‐Ag) and non‐antimicrobial agents (MEBO) and saline‐soaked dressings) in facial burns. </p> <p>Data from <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a> not used, it was not stated or verifiable that all participants healed during the study. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of wounds completely healed within 10 days</b> </p> <p><b>(10 days)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.68 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>39<br/>(<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <b><sup>c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There may be little or no difference in the proportion of wounds completely healed within 10 days between SSD and MEBO. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>824 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>774 per 1000<br/>(560 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Change in wound surface area over time or partial healing</b> – not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies measured change in wound surface area over time or partial wound healing.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Infection</b> </p> <p>(unclear follow‐up<b>)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.38<br/>(0.12 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/>(<a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether Aquacel Ag increases or reduces the risk of infection compared with MEBO in facial burns as evidence is of very low certainty. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 per 1000<br/>(48 to 484) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MEBO:</b> Moist Exposed Burn Ointment; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>SSD:</b> silver sulphadiazine. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for imprecision: limited number of participants (fewer than 100). </p> <p><sup>b</sup>Downgraded once for unclear selection bias, performance and detection bias: unclear random sequence generation and allocation concealment, lack of blinding participants and providers, unclear blinding outcome assessment. Downgraded once for imprecision: effect estimates could not be calculated, limited number of participants (fewer than 100).<br/><sup>c</sup>Downgraded twice for imprecision: substantial number of events in small number of people (31 events in 39 participants), and a 95% CI including both a substantial (&gt;25%) increase and decrease.<br/><sup>d</sup>Downgraded once for unclear selection bias, performance bias and detection bias, unclear attrition bias: unclear random sequence generation and allocation concealment, lack of blinding participants and providers, unclear blinding outcome assessor, unclear completeness outcome data. Downgraded twice for imprecision: very limited number of events in small‐sized study (11 in 40 participants). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008058-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical antimicrobial compared with alternative antimicrobial agent for facial burns</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Topical antimicrobial compared with alternative antimicrobial agent for facial burns</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with facial burns </p> <p><b>Setting:</b> burn centres </p> <p><b>Intervention:</b> topical antimicrobial </p> <p><b>Comparison:</b> alternative antimicrobial agent </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> <p><b>(follow‐up)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with alternative antimicrobial agent</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with topical antimicrobial</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete wound healing</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies measured time to complete wound healing.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of wounds completely healed</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No studies measured proportion of wounds completely healed.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in wound surface area over time or partial healing (&gt; 95%)</b> </p> <p>(12 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to wound healing was 21.4 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 7.10 days lowe<b>r</b><br/>(16.43 lower to 2.23 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 (<a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in time to wound healing between SSD and cerium‐SSD in facial burns. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Infection</b> </p> <p>(until wound healing)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.73<br/>(0.46 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15<br/>(<a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether mafenide acetate cream and gentamicin differs from mafenide acetate only in the risk of infection in facial burns as evidence is of very low certainty. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>365 per 1000<br/>(230 to 585) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SSD:</b> silver sulphadiazine. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for imprecision: one study with 142 participants, optimal information size not reached. Downgraded once for high risk on performance bias and detection bias, and attrition bias not related to the outcome: lack of blinding participants, providers, and outcome assessor.<br/><sup>b</sup>Downgraded twice for high risk on performance bias, detection bias and reporting bias; and unclear selection and attrition bias; lack of blinding participants, providers, unclear blinding outcome assessor, and reporting bias assessor, in combination with unclear random sequence allocation and concealment. allocation. Also downgraded twice for imprecision: one small‐sized study (15 participants). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008058-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Skin substitute compared with topical antimicrobial agent for facial burns</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Skin substitute compared with topical antibiotic agent for facial burns</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with facial burns </p> <p><b>Setting:</b> burn centres </p> <p><b>Intervention:</b> skin substitute </p> <p><b>Comparison:</b> topical antibiotic agent </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> <p><b>(follow‐up)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with topical antibiotic agent</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with skin substitute</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete wound healing</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies measured time to complete wound healing.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of wounds completely healed</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No studies measured proportion of wounds completely healed.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in wound surface area over time or partial wound healing (&gt; 90%)</b> </p> <p>(until wound healing)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to wound healing was 15 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6 days lower<br/>(8.69 lower to 3.31 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/>(<a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A bioengineered skin substitute (TransCyte) might decrease time to 90% wound healing in facial burns, compared to a non‐specified antimicrobial agent. Data from <a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>, <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>, and <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> not used because of concern of overlapping populations, lack of estimate of variance and comparison of wounds within participants. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Infection</b> </p> <p>(until wound healing and unclear (2x))</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>56<br/>(<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether skin substitutes increase or reduce the risk of infection compared with the use of topical antimicrobial agents in facial burns as evidence is of very low certainty. No events reported in 2 RCTs (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a> (control group not reported)), third RCT reported 4 events in 50 wounds in 25 participants (<a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for risk of bias: unclear selection bias, high risk on performance bias and detection bias: unclear random sequence generation and allocation concealment, lack of blinding participants, providers and outcome assessor. Downgraded once for imprecision: one small‐sized study (34 participants).<br/><sup>b</sup>Downgraded once for risk of bias: unclear selection bias, high risk on performance bias and detection bias: unclear random sequence generation and allocation concealment, lack of blinding patients, providers and outcome assessor. Downgraded twice for imprecision: no (report of) events in two small‐sized studies (44 participants), unclear data in third RCT. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008058-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Miscellaneous treatment compared with miscellaneous treatment for facial burns</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Miscellaneous treatment compared with miscellaneous treatment for facial burns</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with facial burns </p> <p><b>Setting:</b> burn centres </p> <p><b>Intervention:</b> miscellaneous treatment (for details see comments) </p> <p><b>Comparison:</b> miscellaneous treatment (for details see comments) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> <p><b>(follow‐up)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with miscellaneous treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with miscellaneous treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete wound healing</b> </p> <p>(until wound healing)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to complete wound healing was 12.05 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.7 days lower<br/>(3.32 lower to 0.08 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MEBO may slightly reduce mean time to wound healing in facial burns compared with saline‐soaked dressing. </p> <p>Data from <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a> not used, it was not stated or verifiable that all participants healed during the study. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of wounds completely healed in 14 days</b> </p> <p>(14 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.77<br/>(1.87 to 12.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43<br/>(<a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A cream containing Helix Aspersa (Elicina) may slightly increase the proportion completely healed at 14 days in facial burns, compared with MEBO. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>894 per 1000<br/>(351 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in wound surface area over time or partial wound healing</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a> measured change in wound surface area over time, data not reported. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Infection</b> </p> <p>(follow‐up unclear)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43<br/>(<a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether a cream containing Helix Aspersa (Elicina) increases or reduces the risk of infection compared with use of MEBO in facial burns as evidence is of very low certainty. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>MEBO:</b> Moist Exposed Burn Ointment; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for risk of bias due to unclear selection bias, high risk on performance bias and detection bias: unclear random sequence generation and allocation concealment, lack of blinding participants and providers, and unclear blinding outcome assessor. Downgraded once for imprecision: one small‐sized study (40 participants).<br/><sup>b</sup>Downgraded once for risk of bias due to high risk selection bias, performance bias and detection bias. No allocation concealment, lack of blinding providers, unclear blinding outcome assessor unclear similarity at baseline. Downgraded once for imprecision: one small‐sized study (43 participants).<br/><sup>c</sup>Downgraded once for risk of bias due to high risk selection bias, performance bias and detection bias: no allocation concealment, lack of blinding providers, unclear blinding outcome assessor unclear similarity at baseline. Downgraded twice for very serious imprecision: no events in one small‐sized study (43 participants). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008058-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008058-sec-0009"></div> <p>(We have provided a glossary of some of the terms used in this review in <a href="./appendices#CD008058-sec-0135">Appendix 1</a>.) </p> <p>Burn injuries are an important health problem, resulting in 45,000 admissions annually in the US, of which more than 25,000 admissions to hospitals with specialised burn centres (<a href="./references#CD008058-bbs2-0031" title="American Burn Association. Burn incidence and treatment in the United States: 2016. www.ameriburn.org/resources_factsheet.php (accessed 17 August 2016).">American Burn Association 2016</a>). In the UK, approximately 13,000 people a year are admitted to hospital for treatment of burns (<a href="./references#CD008058-bbs2-0059" title="HettiaratchyS , DziewulskiP . ABC of burns: introduction. BMJ2004;328(7452):1366-8.">Hettiaratchy 2004a</a>), while in the Netherlands the annual figure is about 1300 people (<a href="./references#CD008058-bbs2-0048" title="DraismaC . Brandwondenrapportage. Cijfers 2015. Amsterdam (the Netherlands): Veiligheid, 2017.">Draisma 2017</a>), 800 of whom are treated in one of the three Dutch burn centres (<a href="./references#CD008058-bbs2-0049" title="Dutch Burn Repository group. Dutch Burn Repository. R3 Short report 2016 [personal communication]. Draft report sent to M Van Baar June 2017.">Dutch Burn Repository 2017 [pers comm]</a>). Mortality rates from burn injuries have substantially decreased because of major improvements in burn care made in the 20th century. This has resulted in a shift in attention towards the functional outcome after a burn injury rather than mortality (<a href="./references#CD008058-bbs2-0087" title="Van BaarME , Essink-BotML , OenIM , DokterJ , BoxmaH , Van BeeckEF . Functional outcome after burns: a review. Burns2006;32(1):1-9.">Van Baar 2006</a>). The head and neck region is estimated to be the site of burn injury in between 27% and 58% of burn cases (<a href="./references#CD008058-bbs2-0063" title="HoogewerfCJ , Van BaarME , HopMJ , BloemenMC , MiddelkoopE , NieuwenhuisMK . Burns to the head and neck: epidemiology and predictors of surgery. Burns2013;39(6):1184-92.">Hoogewerf 2013a</a>). The face is central to our identity and also provides our most expressive means of communication. Appearance, communication, and other basic senses and abilities such as hearing, smelling and breathing may be affected as a direct result of a facial burn, or its sequelae (<a href="./references#CD008058-bbs2-0082" title="SerghiouMA , HolmesCL , McCauleyRL . A survey of current rehabilitation trends for burn injuries to the head and neck. Journal of Burn Care and Rehabilitation2004;25(6):514-8.">Serghiou 2004</a>). Impaired function and distorted appearance may induce psychological problems, problems with social reintegration and affect quality of life (<a href="./references#CD008058-bbs2-0089" title="Van LoeyNE , Van SonMJ . Psychopathology and psychological problems in patients with burn scars: epidemiology and management. American Journal of Clinical Dermatology2003;4(4):245-72.">Van Loey 2003</a>). </p> <section id="CD008058-sec-0010"> <h3 class="title" id="CD008058-sec-0010">Description of the condition</h3> <p>A burn injury to the skin occurs when some, or all, the different layers of skin are destroyed by physical energy delivered via a hot liquid, flame, contact with a hot surface, ultraviolet/infrared radiation, radioactivity, electricity or chemicals (<a href="./references#CD008058-bbs2-0095" title="World Health Organization. Burns: WHO fact sheet no. 365. April 2014. www.who.int/mediacentre/factsheets/fs365/en/ (accessed 17 August 2016).">WHO 2014</a>). The severity of burn wounds is characterised by their size and depth as well as their location and associated injuries. The size of a burn is measured by the percentage of total body surface area (% TBSA) affected, which is the percentage of the surface area of the skin burned, while the depth of a burn is determined by the layers of skin destroyed. So far, no consensus has been reached on the exact classifications of burns, especially not in relation to the classification of depth. <a href="./references#CD008058-bbs2-0067" title="JaspersME , VlaspolderGL , VloemansAF , De VriesA , BrewinMP , HoeksemaH , et al. Burn wound classification: the past, present and the future. In: Beyond the Skin: New Insights in Burn Care [PhD thesis]. Amsterdam (the Netherlands): Vrije Universiteit, 2018:25-44.">Jaspers 2018</a> proposed a scheme based on a combination of currently used classifications. Burn wounds are classified as either superficial burns, partial‐thickness burns, deep partial‐thickness burns or subdermal burns. In superficial burns, only the epidermal layer is destroyed. Healing generally occurs within 5 to 10 days, resulting in a normal looking skin in one to three weeks with only a chance of pigment changes. In partial thickness burns, the upper part of the dermis is also comprised. However, regeneration of the epidermis is expected within two weeks, with very little, or no, scarring, due to the keratinocytes and epidermal stem cells in the appendages of the dermis (<a href="./references#CD008058-bbs2-0067" title="JaspersME , VlaspolderGL , VloemansAF , De VriesA , BrewinMP , HoeksemaH , et al. Burn wound classification: the past, present and the future. In: Beyond the Skin: New Insights in Burn Care [PhD thesis]. Amsterdam (the Netherlands): Vrije Universiteit, 2018:25-44.">Jaspers 2018</a>). In deep partial‐thickness burns, the epidermis and most of the dermis is destroyed, with damage to the skin appendages including hair follicles. Wound healing is delayed, depending on the surviving keratinocytes and epidermal stem cells in the remaining dermis. It is a general rule that if re‐epithelialisation does not occur within three weeks, then hypertrophic scarring may occur (<a href="./references#CD008058-bbs2-0040" title="ChippE , CharlesL , ThomasC , WhitingK , MoiemenN , WilsonY . A prospective study of time to healing and hypertrophic scarring in paediatric burns: every day counts. Burns &amp; Trauma2017;19(5):3.">Chipp 2017</a>; <a href="./references#CD008058-bbs2-0042" title="CubisonTC , PapeSA , ParkhouseN . Evidence for the link between healing time and the development of hypertrophic scars (HTS) in paediatric burns due to scald injury. Burns2006;32(8):992-9.">Cubison 2006</a>). Subdermal burns involve all the layers of skin and may involve structures underneath, such as muscle and bone, leaving little chance of healing from the epithelial elements at the bottom of the wound. In the case of a very small burn, healing might occur by contraction and growth of epithelial cell from the wound edges. Subdermal burns will nearly always result in hypertrophic (raised) scarring. </p> <p>Subdermal facial burns are rare, since the face's high vascularity rapidly dissipates heat (<a href="./references#CD008058-bbs2-0041" title="ChoiM , PanthakiZJ . Tangential excision of burn wounds. Journal of Craniofacial Surgery2008;19(4):1056-60.">Choi 2008</a>). Facial burns are often caused by flash burns, which usually cause partial‐thickness burns. Nonetheless, subdermal facial burns do occur, especially in flame and contact burns, and in the event of prolonged exposure to a heating source, for example if the person was unconscious or paralysed at the time of accident. In addition, in some places (e.g. nose and ears) facial skin is very thin, and, therefore, more vulnerable to deep burns. When nose and ears are deeply burned, the anatomical structures can change or disappear. Full‐thickness burns often require surgical intervention. In the Netherlands, approximately 20% of the people with head and neck burns treated in a burn centre required primary facial surgery and 5% received facial reconstruction in a later phase (<a href="./references#CD008058-bbs2-0063" title="HoogewerfCJ , Van BaarME , HopMJ , BloemenMC , MiddelkoopE , NieuwenhuisMK . Burns to the head and neck: epidemiology and predictors of surgery. Burns2013;39(6):1184-92.">Hoogewerf 2013a</a>). </p> <p>Immediately after the thermal injury, the surfaces of burn wounds are thought to be sterile, but they are rapidly colonised by a variety of micro‐organisms (<a href="./references#CD008058-bbs2-0051" title="ErolS , AltoparlakU , AkcayMN , CelebiF , ParlakM . Changes of microbial flora and wound colonization in burned patients. Burns2004;30(4):357-61.">Erol 2004</a>; <a href="./references#CD008058-bbs2-0098" title="WysockiAB . Evaluating and managing open skin wounds: colonization versus infection. AACN Clinical Issues2002;13(3):382-97.">Wysocki 2002</a>). About 40% of the burn wound cultures on admission are colonised with one or more potentially pathogenic micro‐organisms (<a href="./references#CD008058-bbs2-0047" title="DokterJ , BrusselaersN , HendriksWD , BoxmaH . Bacteriological cultures on admission of the burn patient: to do or not to do, that's the question. Burns2016;42(2):421-7.">Dokter 2016</a>). These micro‐organisms originate from the patient's own skin, respiratory and gastrointestinal flora, and from contact with contaminated surfaces in the external environment, hands of healthcare workers and even air (<a href="./references#CD008058-bbs2-0051" title="ErolS , AltoparlakU , AkcayMN , CelebiF , ParlakM . Changes of microbial flora and wound colonization in burned patients. Burns2004;30(4):357-61.">Erol 2004</a>; <a href="./references#CD008058-bbs2-0094" title="WeberJ , McManusA , Nursing Committee of the International Society for Burn Injuries. Infection control in burn patients. Burns2004;30(8):A16-24.">Weber 2004</a>; <a href="./references#CD008058-bbs2-0098" title="WysockiAB . Evaluating and managing open skin wounds: colonization versus infection. AACN Clinical Issues2002;13(3):382-97.">Wysocki 2002</a>). Burn wounds provide a favourable niche for microbial colonisation and proliferation because of their protein‐rich environment and avascular necrotic tissue (<a href="./references#CD008058-bbs2-0033" title="BarretJP , HerndonDN . Effects of burn wound excision on bacterial colonization and invasion. Plastic and Reconstructive Surgery2003;111(2):744-50.">Barret 2003</a>; <a href="./references#CD008058-bbs2-0051" title="ErolS , AltoparlakU , AkcayMN , CelebiF , ParlakM . Changes of microbial flora and wound colonization in burned patients. Burns2004;30(4):357-61.">Erol 2004</a>). This avascularity of eschar (necrotic tissue) results in impaired migration of host immune cells and restricts delivery of systemically administered antimicrobial agents to the area. The most common burn wound pathogens are <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> (<a href="./references#CD008058-bbs2-0076" title="NagobaBS , GandhiRC , HartalkarAR , WadherBJ , SelkarSP . Simple, effective and affordable approach for the treatment of burns infections. Burns2010;36(8):1242-7.">Nagoba 2010</a>). Microbial colonisation of burn wounds has been associated with delayed wound healing, increased need for surgical interventions and prolonged length of stay (LOS) at burn centres (<a href="./references#CD008058-bbs2-0091" title="VermeulenH , Van HattemJM , Storm-VerslootMN , UbbinkDT , WesterbosSJ . Topical silver for treating infected wounds. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005486. [DOI: 10.1002/14651858.CD005486.pub2]">Vermeulen 2007</a>). </p> <p>Once 30% of the TBSA has been burned there may be systemic (whole body) responses in addition to local responses. This occurs because of the release of inflammatory mediators at the site of injury (<a href="./references#CD008058-bbs2-0060" title="HettiaratchyS , DziewulskiP . ABC of burns: pathophysiology and types of burns. BMJ2004;328(7453):1427-9.">Hettiaratchy 2004b</a>). Besides generating excessive oedema in burns, these systemic reactions can further compromise the healing of a burn wound, and so it is important to consider adequate local treatment, as well as systemic management of a burn, as this may influence the final outcome of the injury. </p> <p>Another possible outcome of a burn injury is hypertrophic scarring, which occurs when the balance between collagen synthesis and breakdown is disrupted (<a href="./references#CD008058-bbs2-0057" title="HerndonDN . Total Burn Care. 3rd edition. Philadelphia (PA): Saunders Elsevier, 2007.">Herndon 2007</a>). The postburn hypertrophic scar may present itself either as a pink to red in colour and slightly thickened, or as a red to purple inelastic mass of skin tissue. If a hypertrophic scar surrounds openings such as the eyes or mouth, functional impairment of the face can occur. The eyes for instance, may not close, due to the inelasticity and contraction of the hypertrophic skin, and the mouth may not open maximally. Furthermore, these scars can result in discomfort, because of itching, and sometimes cause neuropathic (nerve) pain (<a href="./references#CD008058-bbs2-0090" title="Van LoeyNE , BremerM , FaberAW , MiddelkoopE , NieuwenhuisMK . Itching following burns: epidemiology and predictors. British Journal of Dermatology2008;158(1):95-100.">Van Loey 2008</a>). The degree of hypertrophic scarring differs among individuals and depends on a variety of factors, one of which is time to wound healing, with hypertrophic scar formation being seen more often when wound healing takes more than 21 days (<a href="./references#CD008058-bbs2-0040" title="ChippE , CharlesL , ThomasC , WhitingK , MoiemenN , WilsonY . A prospective study of time to healing and hypertrophic scarring in paediatric burns: every day counts. Burns &amp; Trauma2017;19(5):3.">Chipp 2017</a>; <a href="./references#CD008058-bbs2-0042" title="CubisonTC , PapeSA , ParkhouseN . Evidence for the link between healing time and the development of hypertrophic scars (HTS) in paediatric burns due to scald injury. Burns2006;32(8):992-9.">Cubison 2006</a>). In general, a deeper burn wound results in the formation of more hypertrophic tissue. Other factors that have been found to be related to scar formation are female gender, young age, burn size, burns of the neck or upper limb, more than one surgical operation and meshed skin grafts (<a href="./references#CD008058-bbs2-0052" title="GangemiEN , GregoriD , BerchiallaP , ZingarelliE , CairoM , BolleroD , et al. Epidemiology and risk factors for pathologic scarring after burn wounds. Archives of Facial Plastic Surgery2008;10(2):93-102.">Gangemi 2008</a>; <a href="./references#CD008058-bbs2-0088" title="Van der WalM , VloemansJ , TuinebreijerW , Van de VenP , Van UnenE , Van ZuijlenP , et al. Outcome after burns: an observational study on burn scar maturation and the predictors for severe scarring. Wound Repair and Regeneration2012;20(5):676-87.">Van der Wal 2012</a>). </p> </section> <section id="CD008058-sec-0011"> <h3 class="title" id="CD008058-sec-0011">Description of the intervention</h3> <p>The focus of this review is topical treatment for facial burns. Topical treatment comprises any remedy, agent, substance, device or skin substitute that is placed on the face as a therapy for burn wounds. Interventions used in the topical treatment of facial burns can be divided into five main categories: topical antimicrobial agents; topical non‐antimicrobial agents; skin substitutes; wound preparation agents and antiseptics; and miscellaneous treatments, including alternative remedies. This definition excludes invasive surgical intervention, which is another important treatment in burn care. It also excludes negative pressure wound therapy. Numerous dressings and topical ointments are used to treat facial burns (<a href="./references#CD008058-bbs2-0045" title="De HaasKP , BeerthuizenGI , NieuwenhuisMK . Strategies in the treatment of facial burns among the European Burn Centres. In: Proceedings of 11th European Burns Association Congress; 2005 Sept 21-24; Estoril, Portugal. 2005:70.">De Haas 2005</a>; <a href="./references#CD008058-bbs2-0056" title="HansenSL , AlbrechtR , KoteraS , HenningJ , VoigtDW , WiebelhausP , et al. Management of facial burns in the United States. In: 36th Annual Meeting of the American Burns Association; 2004 Mar 24-6; Vancouver (Canada). 2004:S100.">Hansen 2004</a>). Before applying topical or surgical treatment, a burn wound surface might need additional preparation in the form of debridement (removal of dead tissue). The debridement of burns is divided into two main approaches, namely: </p> <p> <ul id="CD008058-list-0001"> <li> <p>superficial debridement: cleaning the wound surface using a brush, gauze or chemical, and removing the superficial loose wound surface; </p> </li> <li> <p>surgical debridement: the excision of the burn wound, with removal of all non‐vital tissue. </p> </li> </ul> </p> <p>This review considered only superficial debridement.</p> </section> <section id="CD008058-sec-0012"> <h3 class="title" id="CD008058-sec-0012">How the intervention might work</h3> <section id="CD008058-sec-0013"> <h4 class="title">Topical antimicrobial agents</h4> <p>Topical antimicrobial agents are used to control and limit infection, and they are central to topical burn therapy. The ideal topical prophylactic antimicrobial agent would have a broad spectrum of activity with a long duration of action, low toxicity and the ability to penetrate eschar (necrotic tissue) without being absorbed by the body (<a href="./references#CD008058-bbs2-0075" title="MonafoWW , WestMA . Current treatment recommendations for topical burn therapy. Drugs1990;40(3):364-73.">Monafo 1990</a>). Ideal topical antimicrobials do not hamper epithelial outgrowth and deliver a high concentration of active ingredients to devitalised, devascularised and potentially necrotic wounds, helping to provide a favourable wound healing environment. Use of topical antimicrobials may help to minimise wound deepening, and the need for extensive debridement and subsequent grafting. This is fundamentally important for facial wounds, where overzealous debridement may affect function and appearance (<a href="./references#CD008058-bbs2-0073" title="Leon-VillapalosJ , JeschkeMG , HerndonDN . Topical management of facial burns. Burns2008;34(7):903-11.">Leon‐Villapalos 2008</a>). </p> <p>The antimicrobial agents used in burn care include silver preparations. Silver sulphadiazine (SSD), in particular, is widely used and acts on burn eschar to limit the extent of non‐viable tissue in situations where surgery is either not possible, or would not be the immediate first option – as in facial burns (<a href="./references#CD008058-bbs2-0073" title="Leon-VillapalosJ , JeschkeMG , HerndonDN . Topical management of facial burns. Burns2008;34(7):903-11.">Leon‐Villapalos 2008</a>). Cerium nitrate is another antimicrobial agent which penetrates burned tissue and has a broad spectrum of activity against Gram‐positive and Gram‐negative bacteria, and fungal species, especially in combination with SSD. Cerium nitrate also has a hardening effect on burn eschar, which is thought to prevent bacterial ingress and helps maintain a moist wound. Furthermore, cerium is supposed to bind and denature the lipid‐protein complex released from burned skin responsible for the profound immunosuppression associated with major cutaneous burns (<a href="./references#CD008058-bbs2-0030" title="AllgöwerM , SchoenenbergerGA , SparkesBG . Pernicious effectors in burns. Burns2008;34(Suppl 1):S1-55.">Allgöwer 2008</a>; <a href="./references#CD008058-bbs2-0053" title="GarnerJP , HeppellPS . Cerium nitrate in the management of burns. Burns2005;31(5):539-47.">Garner 2005</a>). Despite their popularity and widespread use, silver‐based modalities are not without complications, including frequently observed delayed wound healing, which might be due to the retardation of sloughing in partial‐thickness burns. In addition, increased hypertrophic scarring has been described with SSD; while skin irritation, black staining of the skin and the possibility of systemic absorption of silver have also been reported (<a href="./references#CD008058-bbs2-0032" title="AtiyehBS , CostagliolaM , HayekSN , DiboSA . Effect of silver on burn wound infection control and healing: review of the literature. Burns2007;33(2):139-48.">Atiyeh 2007</a>; <a href="./references#CD008058-bbs2-0078" title="PhamC , GreenwoodJ , ClelandH , WoodruffP , MaddernG . Bioengineered skin substitutes for the management of burns: a systematic review. Burns2007;33(8):946-57.">Pham 2007</a>). Furthermore, <a href="./references#CD008058-bbs2-0093" title="WasiakJ , ClelandH , CampbellF , SpinksA . Dressings for superficial and partial thickness burns. Cochrane Database of Systematic Reviews2013, Issue 3. Art. No: CD002106. [DOI: 10.1002/14651858.CD002106.pub4]">Wasiak 2013</a> concluded in a Cochrane systematic review that "SSD was consistently associated with poorer healing outcomes than biosynthetic, silicon‐coated and silver dressings." </p> <p>Other antimicrobial agents include natrium fusidate and nitrofuran. It has been reported that some antimicrobial medications might delay proper healing mechanisms of the wound (<a href="./references#CD008058-bbs2-0071" title="Le DucQ , BreetveldM , MiddelkoopE , ScheperRJ , UlrichMM , GibbsS . A cytotoxic analysis of antiseptic medication on skin substitutes and autograft. British Journal of Dermatology2007;157(1):33-40.">Le Duc 2007</a>; <a href="./references#CD008058-bbs2-0086" title="TeepeRG , KoebruggeEJ , LöwikCW , PetitPL , BosboomRW , TwissIM , et al. Cytotoxic effects of topical antimicrobial and antiseptic agents on human keratinocytes in vitro. Journal of Trauma1993;35(1):8-19.">Teepe 1993</a>), and that improper use can contribute to the emergence of resistant microbes (<a href="./references#CD008058-bbs2-0076" title="NagobaBS , GandhiRC , HartalkarAR , WadherBJ , SelkarSP . Simple, effective and affordable approach for the treatment of burns infections. Burns2010;36(8):1242-7.">Nagoba 2010</a>)<i>.</i> </p> <p>Wound dressings are often used to create an optimal environment for epidermal wound healing. For a long time, a moist environment was regarded as optimal (<a href="./references#CD008058-bbs2-0096" title="WinterGD . Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. Nature1962;193:293-4.">Winter 1962</a>), however, in the 1980s, <a href="./references#CD008058-bbs2-0068" title="JonkmanMF . Epidermal Wound Healing Between Moist and Dry. Groningen (the Netherlands): University of Groningen, 1989.">Jonkman 1989</a> suggested that epidermal wound healing is best accelerated in an environment "between moist and dry," (i.e. a more jelly‐like wound exudate environment). Nowadays, several wound dressings have these moist or gel‐forming qualities. Occlusive dressings, such as hydrocolloids and hydrogel dressings, form a moist or jelly‐like environment by incorporating wound fluids into the dressing. Semi‐occlusive dressings (e.g. polyurethane film, foam or a hydrofibre) permit evaporation of excess water and prevent maceration, while maintaining a moist environment. Silicon‐coated nylon dressings function primarily as non‐adherent dressing layers, and, therefore, reduce potential damage during dressing changes (<a href="./references#CD008058-bbs2-0092" title="WalmsleyS . Advances in Wound Management. London (UK): PJB Publications Ltd, 2002.">Walmsley 2002</a>). </p> <p>When these wound dressing include antimicrobial agents, these can be classified as topical antimicrobial agents. </p> </section> <section id="CD008058-sec-0014"> <h4 class="title">Topical non‐antimicrobial agents</h4> <p>Topical non‐antimicrobial agents include all agents and wound dressings without any antimicrobial agent added. Multiple wound dressings do not include antimicrobial agents. Again, occlusive dressings, such as hydrocolloids and hydrogel dressings, semi‐occlusive dressings and silicon‐coated nylon dressings fall into this category. </p> </section> <section id="CD008058-sec-0015"> <h4 class="title">Skin substitutes: biological and bioengineered dressings</h4> <p>Biological dressings (e.g. cadaver allografts (skin from corpses) and porcine (pig) skin xenografts) can be used to treat partial‐thickness burns. These provide temporary wound coverage until full healing can be achieved, or until autografting (skin graft(s) using the patient's own skin) can take place. Another biological dressing, amnion (derived from the membranous sac that surrounds the developing embryo), can be used as a wound dressing for burn treatment as well (<a href="./references#CD008058-bbs2-0058" title="HerndonDN , BranskiLK . Contemporary methods allowing for safe and convenient use of amniotic membrane as a biologic wound dressing for burns. Annals of Plastic Surgery2017;78(2 (Suppl 1)):S9-10. [DOI: 10.1097/SAP.0000000000000979]">Herndon 2017</a>; <a href="./references#CD008058-bbs2-0070" title="KestingMR , WolffKD , Hohlweg-MajertB , SteinstraesserL . The role of allogenic amniotic membrane in burn treatment. Journal of Burn Care and Research2008;29(6):907-16.">Kesting 2008</a>). In addition, bioengineered skin substitutes can be used as 'smart dressings' in topical therapy; these not only provide immediate wound cover, but are also available in large quantities, with a negligible possibility of disease transfer. These dressings have become part of standard care (<a href="./references#CD008058-bbs2-0097" title="WurzerP , KeilH , BranskiLK , ParviziD , ClaytonRP , FinnertyCC , et al. The use of skin substitutes and burn care – a survey. Journal of Surgical Research2016;201(2):293-8.">Wurzer 2016</a>). Costs of bioengineered skin substitutes are sometimes considered substantial (<a href="./references#CD008058-bbs2-0078" title="PhamC , GreenwoodJ , ClelandH , WoodruffP , MaddernG . Bioengineered skin substitutes for the management of burns: a systematic review. Burns2007;33(8):946-57.">Pham 2007</a>), but could be considered to be less substantial if total costs of burn care are taken into account (<a href="./references#CD008058-bbs2-0064" title="HopMJ , BloemenMC , Van BaarME , NieuwenhuisMK , Van ZuijlenPP , PolinderS , et al, TOPSKIN Study Group. Cost study of dermal substitutes and topical negative pressure in the surgical treatment of burns. Burns2014;40(3):388-96. [DOI: 10.1016/j.burns.2013.08.025.]">Hop 2014</a>). </p> </section> <section id="CD008058-sec-0016"> <h4 class="title">Wound preparation agents and antiseptics</h4> <p>Antiseptics are topical agents thought to prevent the growth of pathogenic micro‐organisms without damaging living tissue (<a href="./references#CD008058-bbs2-0077" title="NormanG , ChristieJ , LiuZ , WestbyMJ , JefferiesJM , HudsonT , et al. Antiseptics for burns. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD011821. [DOI: 10.1002/14651858.CD011821.pub2]">Norman 2017</a>). They can be used to cleanse facial burn surfaces after injury, or to prepare wounds for surgical debridement, or the application of a further topical agent. Examples of antiseptics include chlorhexidine digluconate and povidone iodine. Other wound‐preparation agents include enzymatic debriding agents. These agents prepare the wound by chemical debridement, but their use is controversial for facial burns (<a href="./references#CD008058-bbs2-0073" title="Leon-VillapalosJ , JeschkeMG , HerndonDN . Topical management of facial burns. Burns2008;34(7):903-11.">Leon‐Villapalos 2008</a>). </p> </section> <section id="CD008058-sec-0017"> <h4 class="title">Miscellaneous topical treatments, including alternative remedies</h4> <p>Several additional forms of topical therapy are available, including alternative remedies such as honey and Aloe vera. Honey is said to prevent bacterial growth, form a physical barrier, act as an enzymatic debrider, and promote epithelialisation and angiogenesis (formation of new blood vessels). Aloe vera could accelerate the wound healing process and rate of re‐epithelialisation in partial‐thickness burns (<a href="./references#CD008058-bbs2-0074" title="MaenthaisongR , ChaiyakunaprukN , NiruntrapornS , KongkaewC . The efficacy of aloe vera used for burn wound healing: a systematic review. Burns2007;33(6):713-8.">Maenthaisong 2007</a>; <a href="./references#CD008058-bbs2-0084" title="SomboonwongJ , ThanamittramaneeS , JariyapongskulA , PatumrajS . Therapeutic effects of aloe vera on cutaneous microcirculation and wound healing in second degree burn model in rats. Journal of the Medical Association of Thailand2000;83(4):417-25.">Somboonwong 2000</a>). Although honey and Aloe vera are sometimes considered to be antimicrobials, they are more often considered to be alternative treatments with possible antimicrobial/antiseptic properties and they are therefore included in the miscellaneous topical treatment category. Other alternative remedies, such as covering with banana or cabbage leaves, or potato skins, are sometimes used in places where treatment resources are limited (<a href="./references#CD008058-bbs2-0036" title="BitterCC , EricksonTB . Management of burn injuries in the wilderness: lessons from low-resource settings. Wilderness &amp; Environmental Medicine2016;27:519-25. [DOI: 10.1016/j.wem.2016.09.001]">Bitter 2016</a>). Any other topical treatment for facial burns which does not fall into one of the main groups above was included in this category of alternative remedies. </p> </section> </section> <section id="CD008058-sec-0018"> <h3 class="title" id="CD008058-sec-0018">Why it is important to do this review</h3> <p>Treatment of facial burns is more demanding than treatment of burns on other parts of the body, not only because of the location of vital sensory and communication organs but also because the face is highly vascular. This high vascularisation increases the self‐healing potential of facial burns and, therefore, justifies a conservative approach to treatment, though this may require intensive daily care. There is uncertainty about which treatment is the most effective for facial burns, and, consequently, there are large variations in practice (<a href="./references#CD008058-bbs2-0045" title="De HaasKP , BeerthuizenGI , NieuwenhuisMK . Strategies in the treatment of facial burns among the European Burn Centres. In: Proceedings of 11th European Burns Association Congress; 2005 Sept 21-24; Estoril, Portugal. 2005:70.">De Haas 2005</a>; <a href="./references#CD008058-bbs2-0073" title="Leon-VillapalosJ , JeschkeMG , HerndonDN . Topical management of facial burns. Burns2008;34(7):903-11.">Leon‐Villapalos 2008</a>). Since treatment contributes to outcome – which is especially important for facial burns in terms of both physical and psychological functioning – it is important to consider the most effective treatment. </p> <p>Existing guidelines to support clinical decision making in burn care are predominantly practice‐based or are concerned with the general treatment of burns (<a href="./references#CD008058-bbs2-0066" title="International Society for Burn Injuries (ISBI) Practice Guidelines Committee, Steering Subcommittee, Advisory Subcommittee. ISBI practice guidelines for burn care. Burns2016;42(5):953-1021. [DOI: 10.1016/j.burns.2016.05.013]">ISBI 2016</a>). In addition, several systematic reviews have been published in the field of wound care; including reviews on dressings for superficial and partial‐thickness burns (<a href="./references#CD008058-bbs2-0093" title="WasiakJ , ClelandH , CampbellF , SpinksA . Dressings for superficial and partial thickness burns. Cochrane Database of Systematic Reviews2013, Issue 3. Art. No: CD002106. [DOI: 10.1002/14651858.CD002106.pub4]">Wasiak 2013</a>), and the use of honey (<a href="./references#CD008058-bbs2-0069" title="JullAB , CullumN , DumvilleJC , WestbyMJ , DeshpandeS , WalkerN . Honey as a topical treatment for wounds. Cochrane Database of Systematic Reviews2015, Issue 3. Art. No: CD005083. [DOI: 10.1002/14651858.CD005083.pub4]">Jull 2015</a>), Aloe vera (<a href="./references#CD008058-bbs2-0044" title="DatAD , PoonF , PhamKB , DoustJ . Aloe vera for treating acute and chronic wounds. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD008762. [DOI: 10.1002/14651858.CD008762.pub2]">Dat 2012</a>), antiseptics (<a href="./references#CD008058-bbs2-0077" title="NormanG , ChristieJ , LiuZ , WestbyMJ , JefferiesJM , HudsonT , et al. Antiseptics for burns. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD011821. [DOI: 10.1002/14651858.CD011821.pub2]">Norman 2017</a>), and topical silver (<a href="./references#CD008058-bbs2-0085" title="Storm-VerslootMN , VosCG , UbbinkDT , VermeulenH . Topical silver for preventing wound infection. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD006478. [DOI: 10.1002/14651858.CD006478.pub2]">Storm‐Versloot 2010</a>; <a href="./references#CD008058-bbs2-0091" title="VermeulenH , Van HattemJM , Storm-VerslootMN , UbbinkDT , WesterbosSJ . Topical silver for treating infected wounds. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005486. [DOI: 10.1002/14651858.CD005486.pub2]">Vermeulen 2007</a>); however, no review specifically considered facial burns. In conclusion, current published reviews do not address the effectiveness of topical treatment for facial burns. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008058-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008058-sec-0019"></div> <p>To assess the effects of topical interventions on wound healing in people with facial burns of any depth. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008058-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008058-sec-0020"></div> <section id="CD008058-sec-0021"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008058-sec-0022"> <h4 class="title">Types of studies</h4> <p>We considered all randomised controlled trials (RCTs) that evaluated the effects of topical treatments for facial burns. We decided to consider quasi‐RCTs only in the absence of RCTs. </p> </section> <section id="CD008058-sec-0023"> <h4 class="title">Types of participants</h4> <p>We considered studies that included people of any age with a facial burn wound of any degree in any care setting. Any type of burn injury was eligible (flame, scald, chemical, etc). Ocular burn wounds were excluded. </p> </section> <section id="CD008058-sec-0024"> <h4 class="title">Types of interventions</h4> <p>Studies were considered for inclusion if topical therapy was applied and compared with any comparator intervention. We defined topical therapy as any remedy, agent, substance, device or skin substitute (biological or bioengineered) that was applied to the surface of the facial wound in the acute phase with the aim of treating the burn. We defined the acute phase as the period of wound healing that occurred up to wound closure (epithelialisation). We divided the topical interventions considered for inclusion into the following five categories: </p> <p> <ul id="CD008058-list-0002"> <li> <p>topical antimicrobial agents;</p> </li> <li> <p>topical non‐antimicrobial agents;</p> </li> <li> <p>skin substitutes: biological and bioengineered dressings;</p> </li> <li> <p>wound preparation agents and antiseptics;</p> </li> <li> <p>miscellaneous topical treatments, including alternative remedies.</p> </li> </ul> </p> <p>The previously stated definition of topical therapy excluded surgical debridement and negative pressure wound therapy as index interventions in this review. Comparator interventions could include any other intervention, no intervention or a placebo intervention. </p> </section> <section id="CD008058-sec-0025"> <h4 class="title">Types of outcome measures</h4> <p>Study outcomes did not form part of the selection process. We divided outcomes into primary and secondary outcomes. </p> <section id="CD008058-sec-0026"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008058-list-0003"> <li> <p>Time to complete wound healing, or the proportion of the burn wounds completely healed in a specified time period (as defined by trial authors). Both time to wound healing reported as a time to event outcome and mean time to wound healing outcome were included. </p> </li> <li> <p>Change in wound surface area over time, or the proportion of the burn wound completely healed (epithelialised) in a specific time period (as defined by the trial authors). In case of unclear definition of healing, data were included but this was mentioned. </p> </li> <li> <p>Wound infection (as defined by the trial authors). We did not include data on wound colonisation unrelated to infection. </p> </li> </ul> </p> <p>We accepted any definition of change in wound surface area over time, or proportion of wound surface area healed in a specified time period. In addition, we accepted any definition of wound infection. All primary outcomes were assessed as short‐term endpoints (i.e. three months). </p> </section> <section id="CD008058-sec-0027"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008058-list-0004"> <li> <p>Proportion of facial burns requiring surgery (following treatment by topical agent).</p> </li> <li> <p>Scar quality: observed and self‐reported (any definition of scar quality was accepted).</p> </li> <li> <p>Pain (any assessment was accepted).</p> </li> <li> <p>Patient satisfaction (any assessment was accepted).</p> </li> <li> <p>Adverse effects: classified as: diagnosed by a clinician, diagnosed by laboratory results or patient‐reported symptoms. </p> </li> <li> <p>Quality of life (any assessment was accepted).</p> </li> <li> <p>Length of hospital stay (LOS).</p> </li> </ul> </p> <p>Because we anticipated that primary studies would report and analyse secondary outcomes at different time points, we prespecified time points as either short‐term or long‐term. The short‐term endpoints (i.e. up to three months postburn) included the outcomes: pain, patient satisfaction, adverse effects and LOS; the long‐term endpoints (i.e. after three months and up to 12 months postburn) included the outcomes: proportion of facial burns requiring surgery, adverse effects, scar quality and quality of life. </p> </section> </section> </section> <section id="CD008058-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008058-sec-0029"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases to identify reports of relevant clinical trials: </p> <p> <ul id="CD008058-list-0005"> <li> <p>the Cochrane Wounds Specialised Register (searched 18 December 2019);</p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 11) in the Cochrane Library (searched 18 December 2019); </p> </li> <li> <p>Ovid MEDLINE including In‐Process &amp; Other Non‐Indexed Citations (1946 to 18 December 2019); </p> </li> <li> <p>Ovid Embase (1974 to 18 December 2019);</p> </li> <li> <p>EBSCO CINAHL Plus (Cumulative Index to Nursing and Allied Health Literature; 1937 to 18 December 2019). </p> </li> </ul> </p> <p>The search strategies for the Cochrane Wounds Specialised Register, CENTRAL, Ovid MEDLINE, Ovid Embase and EBSCO CINAHL Plus can be found in <a href="./appendices#CD008058-sec-0136">Appendix 2</a>. We combined the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity‐ and precision‐maximising version (2008 revision) (<a href="./references#CD008058-bbs2-0072" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Lefebvre 2019</a>). We combined the Embase search with the Ovid Embase filter developed by the UK Cochrane Centre (<a href="./references#CD008058-bbs2-0072" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Lefebvre 2019</a>). We combined the CINAHL searches with the trial filters developed by the Scottish Intercollegiate Guidelines Network (<a href="./references#CD008058-bbs2-0083" title="Scottish Intercollegiate Guidelines Network (SIGN). Search filters. www.sign.ac.uk/search-filters.html (accessed 18 December 2019).">SIGN 2019</a>). There were no restrictions with respect to language, date of publication or study setting. </p> <p>We also searched the following clinical trials registries:</p> <p> <ul id="CD008058-list-0006"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (searched 18 December 2019); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>) (searched 18 December 2019). </p> </li> </ul> </p> <p>Search strategies for clinical trial registries can be found in <a href="./appendices#CD008058-sec-0136">Appendix 2</a>. </p> <p>Details of the search strategies used for the previous version of the review are given in <a href="./references#CD008058-bbs2-0099" title="HoogewerfCJ , Van BaarME , HopJ , OenIM , MiddelkoopE , NieuwenhuisMK . Topical treatment for facial burns. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD008058. [DOI: 10.1002/14651858.CD008058.pub2]">Hoogewerf 2013b</a>. </p> </section> <section id="CD008058-sec-0030"> <h4 class="title">Searching other resources</h4> <p>We aimed to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, as well as relevant systematic reviews, meta‐analyses and health technology assessment reports. When necessary, we contacted authors of key papers and abstracts to request further information about their trials. We did not perform a separate search for adverse effects of interventions used, we considered adverse effects described in included studies only. </p> </section> </section> <section id="CD008058-sec-0031"> <h3 class="title" id="CD008058-sec-0031">Data collection and analysis</h3> <p>Data collection and analysis were carried out according to methods stated in the published protocol (<a href="./references#CD008058-bbs2-0100" title="Van BaarME , OenIM , MiddelkoopE , NieuwenhuisMK . Topical treatment for facial burns. Cochrane Database of Systematic Reviews2009, Issue 4. Art. No: CD008058. [DOI: 10.1002/14651858.CD008058]">Van Baar 2009</a>), which were based on the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008058-bbs2-0062" title="HigginsJP , AltmanDG , Sterne J (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook.">Higgins 2017</a>). </p> <section id="CD008058-sec-0032"> <h4 class="title">Selection of studies</h4> <p>There were no restrictions on language of publication or publication status. For this update, two review authors (CH and MvB) independently assessed the titles and abstracts of studies identified from the search in terms of their relevance and design. We obtained full versions of articles if they matched the inclusion criteria from this initial assessment. The review authors independently assessed full‐text articles and determined a final selection of trials eligible for this review. A third review author (JH) evaluated any discrepancies and advised in case of disagreement. </p> </section> <section id="CD008058-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (CH and MvB) independently extracted and summarised details of trials using a data extraction sheet. To provide independent data extraction, a third person (Inge Spronk) not involved in one included study, performed data extraction and risk of bias assessment of the study from <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>, together with CH. Data from a paper in the Chinese language was extracted by a member of Cochrane Wounds. We extracted data on the following items: </p> <p> <ul id="CD008058-list-0007"> <li> <p>characteristics of the trial: method of randomisation, setting, location of care, country, source of funding; </p> </li> <li> <p>participants: number, age, gender, type of burn, percentage TBSA burned, burn depth, concurrent illnesses; </p> </li> <li> <p>intervention topical agents: type of dressing, dose used, frequency of dressing changes, time elapsed before treatment, concurrent interventions; </p> </li> <li> <p>comparator intervention: type of dressing, dose used, frequency of dressing changes, time elapsed before treatment, concurrent interventions; </p> </li> <li> <p>outcomes: types of outcomes measured, timing of outcomes;</p> </li> <li> <p>results.</p> </li> </ul> </p> <p>The review authors resolved any discrepancies by discussion with a third review author (MvB, update JH), and contacted the trial authors when information was missing from published reports or clarification was needed. Data from trials published in duplicate were included only once, but were maximally data extracted. </p> <p>In cases where studies potentially contained the same participants, only the study with the largest sample size was included in data synthesis. </p> </section> <section id="CD008058-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (CH and MvB) made systematic and independent assessments of the risk of bias of each trial, using the Cochrane 'Risk of bias' criteria (<a href="./references#CD008058-bbs2-0062" title="HigginsJP , AltmanDG , Sterne J (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook.">Higgins 2017</a>). To provide independent assessment of risk of bias, a third person (Inge Spronk) not involved in one included study and CH performed data extraction and risk of bias assessment of the study from <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>. A member of Cochrane Wounds (Zhenmi Liu) assessed a paper in the Chinese language. The criteria related to the following issues: </p> <p> <ul id="CD008058-list-0008"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants, care providers and outcome assessors;</p> </li> <li> <p>incomplete outcome data: assessment of dropout rate and intention‐to‐treat (ITT) analysis;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other sources of bias: baseline similarity, co‐interventions, compliance, similar timing of outcome assessment. </p> </li> </ul> </p> <p>Risk of bias increases with each criterion that is judged to be negative. A detailed description of criteria for a judgement of 'low risk of bias', 'high risk of bias' or 'unclear risk of bias' is available in <a href="./appendices#CD008058-sec-0137">Appendix 3</a>. Any discrepancies in judgement between the two review authors was resolved by discussion with a third review author (MvB, update JH). Final assessment of risk of bias was presented in a 'Risk of bias' graph (<a href="#CD008058-fig-0001">Figure 1</a>), and a 'Risk of bias' summary (<a href="#CD008058-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD008058-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008058-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008058-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008058-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD008058-sec-0035"> <h4 class="title">Measures of treatment effect</h4> <p>Data analysis was performed according to the Cochrane guidelines (<a href="./references#CD008058-bbs2-0046" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). One review author (MvB) entered quantitative data into Review Manager 5, this was checked by another review author (CH), and analysed using Review Manager 5 (<a href="./references#CD008058-bbs2-0079" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). For each outcome, summary estimates of treatment effect (with 95% confidence intervals (CI)) were calculated for every comparison. Dichotomous outcomes were presented as risk ratios (RR) (see the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>; <a href="./references#CD008058-bbs2-0046" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>) with 95% CI, and continuous outcomes were presented as mean differences (MD) with 95% CI. We intended to use standardised mean differences (SMD) on occasions when studies assessed the same outcome (e.g. quality of life) but measured the outcome in different ways. Time to wound healing was analysed as a survival (time‐to‐event) outcome if possible, using an appropriate analytical method (i.e. hazard ratio; <i>Cochrane Handbook for Systematic Reviews of Interventions</i>; <a href="./references#CD008058-bbs2-0046" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). Where this was not possible, mean time to wound healing was presented. </p> </section> <section id="CD008058-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>We addressed the level at which randomisation occurred in our analysis. In general, the unit of randomisation and measurement was expected to be the patient. In case of a deviation, we contacted the original investigators whenever possible. In cases where no additional information was obtained, we only presented descriptive data in the review. In case of a within‐participant design, data were handled and presented separately. </p> </section> <section id="CD008058-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the original investigators to request missing data whenever possible. In cases where no information was obtained, we presented a narrative summary of available data. </p> <p>If data were not provided in numerical format and only provided in graphs, we planned to estimate the mean scores and SDs from the graphs. If studies did not provide a mean (SD) for continuous data, we contacted the original investigators. If authors did not respond or were unable to provide the additional data, we included whatever data were available. If insufficient data were available for analyses, we only presented descriptive data in the review. If authors of trials provided both intention‐to‐treat and per protocol data, we would have used the intention‐to‐treat data rather than imputing missing data as originally stated in our protocol. </p> </section> <section id="CD008058-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to explore both clinical and statistical heterogeneity. Clinical heterogeneity was assessed using information on type of dressing, dose used and frequency of dressing changes. We planned to test statistical heterogeneity using the Chi<sup>2</sup> test and estimate the amount of heterogeneity using the I<sup>2</sup> statistic (with 95% CI) (<a href="./references#CD008058-bbs2-0061" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>; <a href="./references#CD008058-bbs2-0046" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>), which examines the percentage of total variation across studies due to heterogeneity rather than to chance. </p> <p>The I<sup>2</sup> statistic ranges from 0% to 100%, with higher values indicating greater heterogeneity. An I<sup>2</sup> statistic of 55% to 100% can be interpreted as considerable heterogeneity. </p> </section> <section id="CD008058-sec-0039"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to measure publication bias using the Begg funnel plot (<a href="./references#CD008058-bbs2-0035" title="BeggCB , MazumdarM . Operating characteristics of a rank correlation test for publication bias. Biometrics1994;50(4):1088-101.">Begg 1994</a>), and the Egger test (<a href="./references#CD008058-bbs2-0050" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>), if the included studies were homogeneous and sufficient in number. </p> </section> <section id="CD008058-sec-0040"> <h4 class="title">Data synthesis</h4> <p>We planned to perform a meta‐analysis for each primary outcome if clinical and statistical homogeneity indicated this would be appropriate (<a href="./references#CD008058-bbs2-0061" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>), and calculate summary estimates of treatment effect for every comparison. </p> <p>No totals were calculated if trial heterogeneity was considerable (I<sup>2</sup> greater than 75%). If pooling was appropriate (I<sup>2</sup> less than 75%), we used both a fixed‐effect and a random‐effects model. The fixed‐effect model ignores heterogeneity, and gives an estimate of the intervention effect, assuming a single intervention effect. The random‐effects model incorporates heterogeneity among studies (<a href="./references#CD008058-bbs2-0046" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>; <a href="./references#CD008058-bbs2-0065" title="IoannidisJP , PatsopoulosNA , EvangelouE . Uncertainty in heterogeneity estimates in meta-analyses. BMJ2007;335(7626):914-6.">Ioannidis 2007</a>). </p> <p>In the study protocol, we planned to restrict the primary analyses to studies at low risk of bias. We defined studies with low risk of bias as RCTs which fulfilled the three criteria of adequate sequence generation, adequate allocation concealment and blinded outcome assessment. However, we conducted a mainly narrative overview, structured by the type of comparison, because statistical meta‐analyses were inappropriate in some cases. This mainly narrative overview was structured by the type of experimental interventions. </p> <p>With the introduction of 'Summary of findings' tables in this update of the review, we decided to present data for all primary outcomes, structured by the type of experimental interventions. </p> </section> <section id="CD008058-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to investigate heterogeneity through subgroup and sensitivity analysis (<a href="./references#CD008058-bbs2-0046" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>), when there was a sufficient number of studies in the meta‐analysis (i.e. more than 10). We planned to conduct subgroup analysis for: </p> <p> <ul id="CD008058-list-0009"> <li> <p>partial‐thickness burns compared with full‐thickness burns, as the effects of topical interventions were expected to differ between patient groups with different burn depths; </p> </li> <li> <p>adequate concealment of allocation (low risk of bias versus unclear or high risk of bias). </p> </li> </ul> </p> <p>However, in the absence of sufficient studies in the meta‐analyses, we performed no subgroup analyses. </p> </section> <section id="CD008058-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>If there were a sufficient number of studies in the meta‐analysis, we planned to perform a sensitivity analysis showing how conclusions might be affected if studies at high risk of bias were excluded from the analyses. We planned to explore the effect of excluding studies with unclear and inadequate sequence generation and unclear and inadequate allocation concealment within the sensitivity analysis. However, in the absence of sufficient studies in meta‐analyses, we performed no sensitivity analysis. </p> </section> <section id="CD008058-sec-0043"> <h4 class="title">'Summary of findings' tables and GRADE assessment of the certainty of evidence</h4> <p>We included 'Summary of findings' tables in this update, constructed using GRADE Pro/GDT software . </p> <p>We limited the 'Summary of findings' tables to our primary outcomes: time to complete wound healing or the proportion of the burn wounds healed in a specified time period, change in wound surface area over time or the proportion of the burn wound completely healed (epithelialised) in a specific time period, and wound infection. </p> <p>Two review authors assessed the certainty of the evidence (CH and MvB).</p> <p>The certainty of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD008058-bbs2-0081" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Schünemann 2019</a>). We aimed to rate the overall certainty of evidence as high, moderate, low or very low using the GRADE approach (<a href="./references#CD008058-bbs2-0054" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">GRADE 2013</a>; <a href="./references#CD008058-bbs2-0080" title="RyanR , HillS . How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group (CCCG). La Trobe University, Melbourne. Published 1 December 2016. Version 3.0. cccrg.cochrane.org/author-resources (accessed 5 October 2018).">Ryan 2016</a>). </p> <p>Well‐designed and conducted RCTs are rated as high‐certainty evidence. We downgraded the evidence to moderate, low or very low depending on the presence of each of the following factors: </p> <p> <ul id="CD008058-list-0010"> <li> <p>study limitations (risk of bias);</p> </li> <li> <p>indirectness of evidence (directness of evidence);</p> </li> <li> <p>imprecision (precision of results);</p> </li> <li> <p>inconsistency (consistency of results) and</p> </li> <li> <p>publication bias (existence of publication bias).</p> </li> </ul> </p> <p>We downgraded the evidence for the risk of bias domain when studies had been classified at high risk of bias for one or more domains. We downgraded evidence for imprecision if the optimal information size was not met. We downgraded twice for imprecision when there were very few events or CIs around effects included both appreciable benefit and harm, or both (<a href="./references#CD008058-bbs2-0055" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [DOI: 10.1016/j.jclinepi.2011.01.012]">Guyatt 2011</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008058-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008058-sec-0044"></div> <section id="CD008058-sec-0045"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD008058-sec-0172" title="">Characteristics of included studies</a>; <a href="./references#CD008058-sec-0174" title="">Characteristics of ongoing studies</a>; and <a href="./references#CD008058-sec-0173" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD008058-sec-0046"> <h4 class="title">Results of the search</h4> <p>This is an update of a Cochrane Review first published in 2013 (<a href="./references#CD008058-bbs2-0099" title="HoogewerfCJ , Van BaarME , HopJ , OenIM , MiddelkoopE , NieuwenhuisMK . Topical treatment for facial burns. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD008058. [DOI: 10.1002/14651858.CD008058.pub2]">Hoogewerf 2013b</a>). The updated searches (18 December 2019), identified, after initial deduplication, 527 unique records. </p> <p>We identified one additional study after reviewing the reference lists of the included papers (<a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>). The updated search resulted in 528 unique records in total. </p> <p>Together with the four studies awaiting assessment in the previous version of the review (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>), we screened 532 records. </p> <p>Two review authors (CH and MvB) independently assessed the titles and abstracts of these records and judged 21 records from 18 studies to be potentially eligible for the review. </p> <p>Seven new studies were included (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>; <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>). With the five previously included studies there are now 12 included studies in this review. </p> <p>Four studies were excluded in this update because they were not RCTs (<a href="./references#CD008058-bbs2-0025" title="SchulzA , PerbixW , FuchsP , RothermundI , DemirE , SchieferJ . Early enzymatic debridement of deep dermal facial burns – results in acute healing and long-term scar quality compared to surgical treatment. Journal of Burn Care &amp; Research2016;37(Suppl 1):S279. ">Schulz 2016</a>), or they did not involve facial burns (<a href="./references#CD008058-bbs2-0013" title="AboelnagaA , ElmasryM , AdlyOA , ElbadawyMA , AbbasAH , AbdelrahmanI , et al. Microbial cellulose dressing compared with silver sulphadiazine for the treatment of partial thickness burns: a prospective, randomised, clinical trial. Burns2018;44(8):1982-8. ">Aboelnaga 2018</a>; <a href="./references#CD008058-bbs2-0018" title="HundeshagenG , CollinsVN , WurzerP , ShermanW , VoigtCD , Cambiaso-DanielJ , et al. A prospective, randomized, controlled trial comparing the outpatient treatment of pediatric and adult partial-thickness burns with suprathel or Mepilex Ag. Journal of Burn Care &amp; Research2018;39(2):261-7. ">Hundeshagen 2018</a>; <a href="./references#CD008058-bbs2-0022" title="MoenadjatY , SetiabudyR , AstrawinataDA , GumayS . The safety and efficacy of feracrylum as compared to silver sulfadiazine in the management of deep partial thickness burn: a clinical study report. Medical Journal of Indonesia2008;17(4):259-71. ">Moenadjat 2008</a>). With the nine excluded studies in the previous version of the review, there are now 13 excluded studies in this review. </p> <p>Three studies were duplicates and already included in the original review, as a study (<a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>), or in the section studies awaiting assessment (<a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>). </p> <p>An overview of the inclusion of studies from the updated search is presented in the PRISMA study flow diagram (<a href="#CD008058-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD008058-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008058-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008058-sec-0047"> <h4 class="title">Included studies</h4> <p>We included seven new studies (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>; <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>), in addition to the five studies included in the previous review (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>). The characteristics of these studies are described in the <a href="./references#CD008058-sec-0172" title="">Characteristics of included studies</a> table and are summarised below. </p> <section id="CD008058-sec-0048"> <h5 class="title">Healthcare settings</h5> <p>Eleven RCTs took place in burn centres, the healthcare setting of the 12th study was unclear (<a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>). Four studies were conducted in North America (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>; <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>); three in Europe (<a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>), two in the Middle East (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>), and three in Asia (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>). </p> </section> <section id="CD008058-sec-0049"> <h5 class="title">Participants</h5> <p>The 12 included studies recruited 507 participants (range of sample size 10 to 180), although it is possible that this number might be lower due to a possible overlap of participants between two studies (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>), which potentially would decrease the total to 486. Ten studies reported age of included participants and seven studies reported percentage TBSA burned. The mean age varied between 5.3 years (<a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>) up to 41.9 years (intervention group, <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>). The mean percentage TBSA burned varied from 1.56% (control group, <a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>), to 50% (control group, <a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>). Two studies did not provide information on age or percentage TBSA burned (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>). For detailed information see <a href="./references#CD008058-sec-0172" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD008058-sec-0050"> <h5 class="title">Interventions</h5> <p>Three studies compared topical antimicrobial versus non‐antimicrobial agents. These studies included comparisons between SSD and the non‐antimicrobial Moist Exposed Burn Ointment (MEBO) (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>), and between a topical antimicrobial hydrocolloid dressing (Aquacel Ag) and MEBO (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>). </p> <p>Two studies compared topical antimicrobials with an alternative topical antimicrobial agent. One study compared cerium nitrate‐SSD (CN‐SSD) with SSD (<a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>), and one study compared an antimicrobial agent (i.e. 1% gentamicin cream) administered via iontophoresis in combination with mafenide acetate compared with mafenide acetate alone (<a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>). </p> <p>Four studies compared skin substitutes with topical antimicrobial agents (<a href="#CD008058-tbl-0005">Table 1</a>). The skin substitutes included bioengineered skin substitutes (TransCyte), allograft (glycerolised cadaver skin), and a biological skin substitute (porcine Xenoderm) (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>). These skin substitutes were compared with the antimicrobial agents Bacitracin, SSD and Physiotulle Ag. </p> <div class="table" id="CD008058-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of studies for comparisons: interventions and primary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time to wound healing</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in wound surface area, proportion of wound partly healed</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Complete healing data reported?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Infection</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Topical antimicrobial agent compared with topical non‐antimicrobial agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SSD vs</p> <p>MEBO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to event analysis, days to complete wound healing; number of participants healed at 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver hydrocolloid dressing (Aquacel Ag) vs MEBO vs saline‐soaked dressings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver hydrocolloid dressing (Aquacel Ag) vs MEBO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated nor verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported,<br/>not prespecified, no definition </p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Topical antimicrobial agents compared with other topical antimicrobial agents</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mafenide acetate cream + gentamicin via iontophoresis (7 participants) vs usual care (mafenide acetate cream) (8 participants) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical features</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerium‐SSD vs SSD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to event anaysis, days to 90% wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Skin substitutes compared with topical antimicrobial agents</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biological skin substitute coated with fibronectin (TransCyte) vs Bacitracin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to 95% wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical features</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bioactive skin substitute (a bilayered, biologically active, temporary skin substitute (TransCyte)) vs antibacterial ointment, not specified </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to 90% wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycerolised allograft cadaver (corpse) skin vs SSD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months (maximum)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in 1 group, not prespecified, no definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biological dressing (porcine Xenoderm) vs Physiotulle Ag (Coloplast)</p> <p>50 wounds in 25 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months (scar)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to 95% wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical features</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Miscellaneous treatment compared with miscellaneous treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MEBO vs saline‐soaked dressing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rhGM‐CSF hydrogel (1 μg/cm<sup>2</sup>/day) vs placebo hydrogel (matrix hydrogel) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% wound healing at 3, 5, 7 and 14 days after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enzymatic debridement (collagenase) vs antimicrobial agent (Bacitracin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a><a href="https://archie.cochrane.org/sections/documents/view?version=z1901161709573099519576834183040&amp;format=REVMAN#STD-NCT01668030" target="_blank">0</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wound epithelialisation: time to establish a wound bed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Documented wound or blood infection confirmed by a positive laboratory result.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cream containing Helix Aspersa extract (terrestrial brown snail secretions extract (Elicina) vs MEBO </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years (scar)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing, number of participants healed at 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated or verifiable (days to complete wound healing)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Burn swab cultures; systemic infections,<br/>not prespecified </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MEBO: Moist Exposed Burn Ointment; rhGM‐CSF: recombinant human granulocyte‐macrophage colony‐stimulating factor; SSD: silver sulphadiazine. </p> </div> </div> <p>Finally, four studies included comparisons of a variety of topical interventions, including the comparison of saline‐soaked dressings to sodium carboxymethyl‐cellulose silver (Aquacel Ag) and MEBO (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>), the comparison of growth hormone therapy (recombinant human granulocyte‐macrophage colony‐stimulating factor hydrogel, rhGM CS) to a placebo hydrogel (<a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>), the comparison of enzymatic debridement to a topical antimicrobial agent (<a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>), and a comparison of a cream containing Helix Aspersa extract (Elicina) to MEBO (<a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>). </p> </section> <section id="CD008058-sec-0051"> <h5 class="title">Outcomes</h5> <p>Seven of 12 studies included 'time to complete wound healing' as an outcome of interest (<a href="#CD008058-tbl-0005">Table 1</a>). In addition, two studies reported the number of participants healed at 10 days (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>) and 14 days (<a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>). Five studies used 'change in wound surface area over time,' or 'the proportion of the burn wounds partly healed' as an outcome measure, by assessing the percentage wound healing at 3, 5, 7 and 14 days after treatment (<a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>), or the time to 90% or 95% wound healing (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>). </p> <p>Ideally 'time to wound healing' should be measured as a time‐to‐event outcome and reported in survival curves and expressed as hazard ratios. Only two studies (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>, <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>) analysed time to wound healing properly, as a time‐to‐event outcome. For studies that reported on 'time to wound healing', if all the recruited participants did not heal within the study period it would have been wrong to report mean time to wound healing. Three out of 12 studies stated that all participants healed during the study, and in six studies this was verifiable, in the other three studies this was not stated or verifiable (<a href="#CD008058-tbl-0005">Table 1</a>). </p> <p>Wound infection was a prespecified outcome in four studies (and another three studies reported this outcome although it had not been prespecified in the methods section (<a href="#CD008058-tbl-0005">Table 1</a>)). Two studies assessed bacterial wound colonisation only (<a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>); these data were not included in the review. </p> <p>Secondary outcomes reported in the included studies included the proportion of facial burns requiring surgery, pain, scar quality, patient satisfaction, LOS and adverse effects (<a href="#CD008058-tbl-0006">Table 2</a>). </p> <div class="table" id="CD008058-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of studies for comparisons: interventions and secondary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Scar quality</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Patient satisfaction</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>QoL</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>LOS</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="top"> <p><b>Topical antimicrobial agent compared with topical non‐antimicrobial agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SSD vs MEBO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reconstructive surgery, following wound closure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver hydrocolloid dressing (Aquacel Ag) vs MEBO vs saline‐soaked dressings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until</p> <p>wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of healing (4‐point scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐point scale (excellent‐ poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver hydrocolloid dressing (Aquacel Ag) vs MEBO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vancouver Scar Scale, incidence hypertrophic scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐point scale: (comfortable‐discomfortable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="top"> <p><b>Topical antimicrobial agents compared with other topical antimicrobial agents</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mafenide acetate cream and gentamicin via iontophoresis (7 participants) vs usual care (mafenide acetate cream) (8 participants) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery, following treatment by topical agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerium‐SSD vs SSD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery, following treatment by topical agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>POSAS, colour (dermaspectometer), elasticity (cutometer), functional and anatomical impairments </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAT (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="top"> <p><b>Skin substitutes compared with topical antimicrobial agents</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biological skin substitute coated with fibronectin (TransCyte) vs Bacitracin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bioactive skin substitute (a bilayered, biologically active, temporary skin substitute (TransCyte)) vs antibacterial ointment, not specified </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycerolised allograft cadaver (corpse) skin vs SSD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months (maximum)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biological dressing (porcine Xenoderm) vs Physiotulle Ag (Coloplast)</p> <p>50 wounds in 25 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months (scar)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vancouver Scar Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="top"> <p><b>Miscellaneous treatment compared with miscellaneous treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MEBO vs saline‐soaked dressing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of healing (4‐point scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enzymatic debridement (Collagenase) vs antimicrobial agent (Bacitracin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>POSAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality, serious adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cream containing Helix Aspersa extract (Elicina) vs MEBO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years (scar)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (1–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LOS: length of hospital stay; MEBO: Moist Exposed Burn Ointment; POSAS: Patient and Observer Scar Assessment Scale; QoL: quality of life; SSD: silver sulphadiazine; VAS: visual analogue scale. </p> </div> </div> </section> <section id="CD008058-sec-0052"> <h5 class="title">Sponsorship</h5> <p>Six of 12 studies explicitly stated that the authors had no conflict of interest (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>), while the authors of other studies provided no information about sponsorship (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>; <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>; <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>). In three of these five studies, the intervention was an explicitly mentioned brand, but it was not stated whether this application was sponsored or purchased (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>). </p> </section> </section> <section id="CD008058-sec-0053"> <h4 class="title">Excluded studies</h4> <p>Four additional potentially eligible studies were excluded in this update. Full‐text analysis resulted in four exclusions because the study was not an RCT (<a href="./references#CD008058-bbs2-0025" title="SchulzA , PerbixW , FuchsP , RothermundI , DemirE , SchieferJ . Early enzymatic debridement of deep dermal facial burns – results in acute healing and long-term scar quality compared to surgical treatment. Journal of Burn Care &amp; Research2016;37(Suppl 1):S279. ">Schulz 2016</a>), or did not involve facial burns (<a href="./references#CD008058-bbs2-0013" title="AboelnagaA , ElmasryM , AdlyOA , ElbadawyMA , AbbasAH , AbdelrahmanI , et al. Microbial cellulose dressing compared with silver sulphadiazine for the treatment of partial thickness burns: a prospective, randomised, clinical trial. Burns2018;44(8):1982-8. ">Aboelnaga 2018</a>; <a href="./references#CD008058-bbs2-0018" title="HundeshagenG , CollinsVN , WurzerP , ShermanW , VoigtCD , Cambiaso-DanielJ , et al. A prospective, randomized, controlled trial comparing the outpatient treatment of pediatric and adult partial-thickness burns with suprathel or Mepilex Ag. Journal of Burn Care &amp; Research2018;39(2):261-7. ">Hundeshagen 2018</a>; <a href="./references#CD008058-bbs2-0022" title="MoenadjatY , SetiabudyR , AstrawinataDA , GumayS . The safety and efficacy of feracrylum as compared to silver sulfadiazine in the management of deep partial thickness burn: a clinical study report. Medical Journal of Indonesia2008;17(4):259-71. ">Moenadjat 2008</a>). </p> <p>In the original review, nine studies (10 records) were excluded because they were not RCTs (<a href="./references#CD008058-bbs2-0015" title="BranskiLK , HerndonDN , CelisMM , NorburyWB , MastersOE , JeschkeMG . Amnion in the treatment of pediatric partial-thickness facial burns. Burns2008;34(3):393-9. [DOI: 10.1016/j.burns.2007.06.007]BranskiLK , HerndonDN , NorburyWB , CelisM , MastersOE , JeschkeMG . Amnion in the treatment of pediatric facial partial-thickness burns. Journal of Burn Care and Research2007;28(2):S106. ">Branski 2008</a>; <a href="./references#CD008058-bbs2-0016" title="CoveyMH , PrestigiacomoMJ , EngravLH . Management of face burns. Topics in Acute Care and Trauma Rehabilitation1987;1(4):40-9. ">Covey 1987</a>; <a href="./references#CD008058-bbs2-0017" title="HartmannB , EkkernkampA , JohnenC , GerlachJC , BelfekrounC , KüntscherMV . Sprayed cultured epithelial autografts for deep dermal burns of the face and neck. Annals of Plastic Surgery2007;58(1):70-3. [DOI: 10.1097/01.sap.0000250647.39784.bb]">Hartmann 2007</a>; <a href="./references#CD008058-bbs2-0019" title="LansdownAB , WilliamsA . How safe is silver in wound care?Journal of Wound Care2004;13(4):131-6. ">Lansdown 2004</a>; <a href="./references#CD008058-bbs2-0020" title="Li H-M, Liang Z-Q, Meng C-Y. Comparison of repaired effect of recombinant human epidermal growth factor for the facial burn wounds of degree II. Chinese Journal of Clinical Rehabilitation2005;9(34):110-1. ">Li 2005</a>; <a href="./references#CD008058-bbs2-0021" title="LiangZQ , LiHM , MengCY . Repair of second degree facial burns in children using recombinant human epidermal growth factor. Journal of Clinical Rehabilitative Tissue Engineering Research2007;11(10):1974-5. ">Liang 2007</a>; <a href="./references#CD008058-bbs2-0023" title="PappT , MénesiL , SzalaiI . Experiences in the Ebrimycin® gel treatment of burns. Therapia Hungarica (English Edition)1990;38(3):125-8. ">Papp 1990</a>), or because the focus of the study was not on facial burns (<a href="./references#CD008058-bbs2-0014" title="AngES , Lee S-T, GanCS , SeePG , Chan Y-H, Ng L-H, et al. Evaluating the role of alternative therapy in burn wound management: randomized trial comparing moist exposed burn ointment with conventional methods in the management of patients with second-degree burns. Medscape/General Medicine2001;3(12):3-18. ">Ang 2001</a>; <a href="./references#CD008058-bbs2-0024" title="RegeNN , DahanukarSA , GindeVK , ThatteUM , BapatRD . Safety and efficacy of Azadirachta indica in patients with second degree burns. Indian Practitioner1999;52(4):240-8. ">Rege 1999</a>). </p> <p>The total number of excluded studies is now 13.</p> </section> <section id="CD008058-sec-0054"> <h4 class="title">Studies awaiting assessment</h4> <p>No studies are awaiting classification.</p> </section> <section id="CD008058-sec-0055"> <h4 class="title">Ongoing studies</h4> <p>Four studies are ongoing and have been detailed in the <a href="./references#CD008058-sec-0174" title="">Characteristics of ongoing studies</a> table (<a href="./references#CD008058-bbs2-0026" title="ACTRN12615001205527. White soft paraffin vs Glucan Pro 3000 ointment for face burns. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369444 (first received 6 October 2015). ">ACTRN12615001205527</a>; <a href="./references#CD008058-bbs2-0027" title="ACTRN12618001631291. Comparison of the outcome (in terms of mean healing time) of amnion versus conventional antimicrobial ointment alone in facial burn patients: a randomized control trial. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=376027 (first received 3 October 2018). ">ACTRN12618001631291</a>; <a href="./references#CD008058-bbs2-0028" title="ACTRN12619001050145. Outcome of cellular versus acellular amnion in superficial facial burn: a randomized trial. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377782 (first received 16 June 2019). ">ACTRN12619001050145</a>; <a href="./references#CD008058-bbs2-0029" title="TCTR20171004003. A prospective randomized control trial comparing the effect of chloramphenicol ointment with recombinant human epidermal growth factor on second degree facial burn wound healing. apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20171004003 (first received 1 October 2017). ">TCTR20171004003</a>). </p> </section> </section> <section id="CD008058-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p>In most studies, there was a high risk of bias related to blinding (performance and detection bias), whereas the risk of bias related to random sequence and allocation concealment (selection bias) was often unclear. The risk of bias judgements are presented in the 'Risk of bias' summary (<a href="#CD008058-fig-0002">Figure 2</a>) (part of <a href="./references#CD008058-sec-0172" title="">Characteristics of included studies</a> table), and the 'Risk of bias' graph (<a href="#CD008058-fig-0001">Figure 1</a>), and are described below. </p> <section id="CD008058-sec-0057"> <h4 class="title">Allocation</h4> <p>Of the 12 included studies, only three studies adequately described the method of sequence generation (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>), and two studies adequately described the method of allocation concealment (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>). <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a> did not report on allocation concealment, but added in a personal communication, "the generator was used by the resident responsible for admitting the patient, who also checked for eligibility." This, in combination with the unequal number of randomised participants per group (27 versus 19) resulted in a judgement of high risk of bias. The other studies stated that participants were randomised, but did not describe the method of sequence generation or allocation concealment (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>; <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>; <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a><a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>). </p> </section> <section id="CD008058-sec-0058"> <h4 class="title">Blinding</h4> <p>Review authors had to judge the blinding of participants, care providers and outcome assessors. One of 12 studies reported blinding of participants, care providers and assessors (<a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>), one study reported blinding of participants and outcome assessors (personal communication, <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>), and one study reported blinding of outcome assessors only (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>). <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a> did not report blinding, but used recombinant human granulocyte‐macrophage stimulating factor (rhGMCSF) hydrogel and a placebo hydrogel (matrix hydrogel), suggesting that at least participants were blinded. In almost all studies, the nature of treatments made it impossible to blind participants and care providers and thus the review authors made a judgement of 'no' rather than one of 'unclear.' Three studies reported blinding of outcome assessors (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>); four studies clearly did not undertake blinded outcome assessment (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>), and in five studies it was unclear whether the outcome assessor was blinded (<a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>; <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>; <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>). </p> </section> <section id="CD008058-sec-0059"> <h4 class="title">Incomplete outcome data</h4> <p>The item 'incomplete outcome data' includes a high dropout rate or an imbalance in dropout in combination with an absent ITT analysis. Seven studies showed no risk of attrition bias (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>; <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>), in four studies risk of bias was unclear (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>; <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>), and one study had a high risk of bias because of high dropout (<a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>). </p> <p>The dropout rate was described and acceptable (i.e. did not exceed 20% for short‐term follow‐up and 30% for long‐term follow‐up and did not lead to substantial bias) in seven studies (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>; <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>), while four studies did not report it or made it evident in the presentation of the outcome data (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>; <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>). In <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>, loss to follow‐up was high (maximum 24.4% at 3 months, 34.2% at 6 months and 39.5% at 12 months); additional information on reasons for dropout were reported. Loss to follow‐up was related to shorter hospital stay and smaller burn size. </p> <p>An imbalance in dropout in combination with a lack of ITT analysis was not observed. Two studies performed ITT analyses (<a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>); another six studies did not report ITT analysis specifically, but it appeared likely when the studies were assessed (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>; <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>). One study stated that ITT analysis was performed, but assessment of the study showed clearly that it had not (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>). The final three studies were unclear on this topic (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>; <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>). </p> </section> <section id="CD008058-sec-0060"> <h4 class="title">Selective reporting</h4> <p>Nine studies were free of the suggestion of selective outcome reporting (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>), in one study the reporting was unclear in the absence of sufficient information (no protocol or full‐text paper available) (<a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>), and in two studies risk of reporting bias seemed apparent (<a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>; <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>). <a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a> listed wound healing as an outcome of interest but did not report it in the results section. <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a> assessed wound infection, pain and scar quality but did not report the results. </p> </section> <section id="CD008058-sec-0061"> <h4 class="title">Other potential sources of bias</h4> <p>Potential sources of bias existed in three studies, especially related to baseline characteristics. In two studies, the description of baseline characteristics was limited to only one important prognostic indicator (respectively %TBSA burned and age (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>)), which was insufficient to make a judgement of low risk of bias for baseline similarity. In a third study, the %TBSA burned in both groups was not similar and no information was provided about aetiology (<a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>). </p> <p>Bias related to co‐interventions was assessed and limited; three studies avoided (or similar) co‐interventions (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>); four studies provided no information about co‐interventions (<a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>; <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>; <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>), and another three studies presented small differences in treatment procedures in the methods sections (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>) or stated "subsequent care in the intervention group when needed" without reporting whether this care was applied (<a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>). </p> <p>Due to the within‐participant design of two studies (i.e. two wounds in one participant), risks of above‐described sources of bias were small (<a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>). Baseline characteristics (i.e. age and %TBSA burned) did not differ and co‐interventions affected both wounds of the participant, except where localised co‐interventions were applied. </p> <p>There were no specific unit of analysis issues. Two studies used a within‐participant design; one study did not conduct an appropriate analyses, reflecting the paired data (<a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>). </p> </section> </section> <section id="CD008058-sec-0062"> <h3 class="title" id="CD008058-sec-0062">Effects of interventions</h3> <p>See: <a href="./full#CD008058-tbl-0001"><b>Summary of findings 1</b> Topical antimicrobial agent compared with topical non‐antimicrobial agent for facial burns</a>; <a href="./full#CD008058-tbl-0002"><b>Summary of findings 2</b> Topical antimicrobial compared with alternative antimicrobial agent for facial burns</a>; <a href="./full#CD008058-tbl-0003"><b>Summary of findings 3</b> Skin substitute compared with topical antimicrobial agent for facial burns</a>; <a href="./full#CD008058-tbl-0004"><b>Summary of findings 4</b> Miscellaneous treatment compared with miscellaneous treatment for facial burns</a> </p> <p>The effects of topical agents on facial burns are summarised in <a href="./full#CD008058-tbl-0001">summary of findings Table 1</a>: topical antimicrobial agent compared with topical non‐antimicrobial agent; <a href="./full#CD008058-tbl-0002">summary of findings Table 2</a>: topical antimicrobial agents compared with other topical antimicrobial agents; <a href="./full#CD008058-tbl-0003">summary of findings Table 3</a>: skin substitutes compared with topical antimicrobial agents; and <a href="./full#CD008058-tbl-0004">summary of findings Table 4</a>: miscellaneous treatment compared with miscellaneous treatment. </p> <p>In addition, effects of interventions in individual studies are presented in <a href="#CD008058-tbl-0007">Table 3</a>. </p> <div class="table" id="CD008058-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results from included trials</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main baseline characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants and dropout rate</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Primary outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Secondary outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants:</p> <p>I: 22; C: 17.</p> <p>% TBSA burned (mean):</p> <p>I: 1.56 (SE 0.18; range 0.5–3.5).</p> <p>C: 2.16 (SE 0.38; range 0.13–6.0).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 115.</p> <p>After randomisation: I: 58; C: 57.</p> <p>Dropouts: I: 0; C:3.</p> <p>Participants with facial burns: I: 22; C:17.</p> <p>Participants in short‐term analysis:</p> <p>I: 22; C:17.</p> <p>Participants in long‐term analysis (6 months):</p> <p>I: 20; C:17.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing (number of days taken for face‐wound to heal):</p> <p>I: not reported; C: 2–35 days (range).</p> <p>Proportion completely healed in 10 days:</p> <p>I: 17/22; C: 14/17.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for surgery (need for reconstructive surgery 6 months PB):</p> <p>I: 0/20; C: 0/17.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants:</p> <p><i>Minor burns:</i> I: 5; C: 5.<br/><i>Major burns:</i> I: 5; C: 6. </p> <p>Mean age:</p> <p><i>Minor burns:</i> I: 31 (SD 8) years; C: 29 (SD 7) years<i>.</i> <br/><i>Major burns:</i> I: 44 (SD 10) years; C: 40 (SD 8 years)<i>.</i> </p> <p>Aetiology: flame.</p> <p>% TBSA burned (mean):</p> <p><i>Minor burns:</i> I: 10 (SD 3); C: 7 (SD 2)<i>.</i> <br/><i>Major burns:</i> I: 32 (SD 9); C: 30 (SD 8)<i>.</i> </p> <p>% TBSA burned full‐thickness (mean):</p> <p><i>Minor burns:</i> I: 0; C: 0<i>.</i> <br/><i>Major burns:</i> I: 10 (SD 3); C: 8 (SD 2)<i>.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 21.</p> <p>Number of participants with minor burns: 10.</p> <p>Number of participants with major burns: 11.</p> <p>After randomisation:</p> <p><i>Minor burns:</i> I: 5; C: 5<i>.</i> <br/><i>Major burns:</i> I: 5; C: 6<i>.</i> </p> <p>Participants in short‐term analysis:</p> <p><i>Minor burns:</i> I: 5; C: 5<i>.</i> <br/><i>Major burns:</i> I: 5; C: 6<i>.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to partial wound healing</p> <p>(mean number of days to &gt; 90% re‐epithelialisation):</p> <p><i>Minor burns:</i> I: 8 (SD 1); C: 12 (SD 3); reported P &lt; 0.05. </p> <p><i>Major burns:</i> I: 8 (SD 2); C: 14 (SD 4); reported P &lt; 0.05. </p> <p>Wound infection (signs of local wound infection):</p> <p><i>Minor burns:</i> I: 0; C: 0.<br/><i>Major burns:</i> I: 0; C: 0. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain (procedural pain, during facial care (mean):</p> <p><i>Minor burns:</i> I: 2 (SD 1); C: 5 (SD 1).<br/><i>Major burns:</i> I: 2 (SD 1); C: 5 (SD 1). </p> <p>Pain (background pain, between facial care) (mean):</p> <p><i>Minor burns:</i> I: 1 (SD 0.5); C: 3 (SD 2).<br/><i>Major burns:</i> I: 2 (SD 1); C: 4 (SD 2). </p> <p>Length of stay (mean):</p> <p><i>Minor burns:</i> I: 1 (SD 0.5); C: 3 (SD 1).<br/><i>Major burns:</i> not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I: 16; C: 18.</p> <p>Mean age: I: 39 (SD 9); C: 40 (SD 8).</p> <p>Aetiology:</p> <p><i>Flame:</i> I: 11; C: 12<i>.</i> <br/><i>Scald:</i> I: 5; C: 6. </p> <p>% TBSA burned (mean): I: 24 (SD 8); C: 21 (SD 9).</p> <p>% TBSA burned full‐thickness (mean): I: 12 (SD 7); C: 10 (SD 6).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 34.</p> <p>After randomisation:</p> <p>I: 16; C: 18.</p> <p>Participants in short‐term analysis:</p> <p>I: 16; C: 18.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to partial wound healing (mean number of days to &gt; 95% re‐epithelialisation:</p> <p>I: 9 (SD 4); C: 15 (SD 4); reported P &lt; 0.05.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain (procedural pain, during facial care) (mean): I: 3 (SD 1); C: 7 (SD 2).</p> <p>Pain (background pain, between facial care) (mean): I: 2 (SD 1); C: 4 (SD 2).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I: 7; C: 8.</p> <p>Mean age: I: 11.4 (SE 1.2); C: 9.5 (SE 1.6).</p> <p>% TBSA burned (mean): I: 35 (SE 7); C: 50 (SE 6).</p> <p>% TBSA burned full‐thickness (mean): I: 20 (SE 9); C: 32 (SE 7).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 15.</p> <p>After randomisation: I: 7; C: 8.</p> <p>Participants in short‐term analysis: I: 7; C: 8.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wound infection (occurrence of chondritis): I: 3; C: 4.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for surgery (mean number of surgical procedures): I: 1.2 (SE 0.1) C: 1.0 (SE 0); reported P &lt; 0.05. </p> <p>Adverse effects (occurrence of gentamicin‐resistant micro‐organisms): I: 29%; C: 0%<i>.</i> </p> <p>Length of stay (mean): I: 26 (SE 1); C: 38 (SE 3).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I: 20; C1; 20; C2: 20.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 60.</p> <p>After randomisation: I: 20; C1: 20; C2: 20.</p> <p>Participants in short‐term analysis: I: 20; C1: 20; C2: 20.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing (mean): I: 10.05 (SD 2.3); C1: 10.35 (SD 2.8); C2: 12.05 (SD 2.4), reported P &lt; 0.05. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain: (mean) day 1 and 2: C1: 3.1 (SD 1.9); day 3 onwards: C1: 1.3 (SD 1.5), I and C2 not presented, least pain in C1, reported P &lt; 0.05). </p> <p>Scar quality (quality of healing): excellent: I: 16; C1: 16; C2: 11, reported P &gt; 0.05. </p> <p>Patient satisfaction: excellent: I: 11; C1: 12; C2: 2, reported P &lt; 0.05.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I: 5; C; 5.</p> <p>Median age I+C: 34.3 (range 24–67) years.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 10.</p> <p>After randomisation: I: 5; C: 5.</p> <p>Participants in short‐term analysis: I: 5; C:5.</p> <p>Participants in long‐term analysis: I: 5; C:5.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing (median)</p> <p>I: 10.5; C: 12.4, reported P &lt; 0.05.</p> <p>Wound infection (signs of underlying infection) I: 0; C: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scar quality (scar formation, maximum 6 months): I: 0; C: 2.</p> <p>Adverse effects (localised partial integration of the biological dressing) I: 1; C: 0. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I+C: 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 30.</p> <p>After randomisation: ?</p> <p>Participants in short‐term analysis: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing</p> <p>(mean): I: 13.47 (SD 1.08) days; C: 18.69 (SD 2.35) days, reported P &lt; 0.01</p> <p>Change in wound surface area over time: percentage of healing at 3, 5, 7 and 14 days after treatment, reported P &lt; 0.01 at day 5, 7 and 14 days after treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: 10 (within patient comparison).</p> <p>Age: 9 participants aged 18–64 years, 1 participant aged ≥ 65 years.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 10.</p> <p>After randomisation: 10.</p> <p>Participants in short‐term analysis: 10.</p> <p>Participants in long‐term analysis: no data provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing (days to complete epithelialisation, mean): I1: 37.6; I2: 37.4, reported P = 0.0853. </p> <p>Wound infection: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain: not reported.</p> <p>Scar quality: not reported.</p> <p>Adverse effects: all‐cause mortality: 1.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I1 (Aquacel Ag): 20; I2 (MEBO): 20.</p> <p>Mean age: I1: 41.4 years, I2: 37.5 years.</p> <p>Total TBSA range: I: 5–30, C: 7–30.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 40.</p> <p>After randomisation: I1: 20; I2: 20.</p> <p>Participants in short‐term analysis: I1: 20; I2: 20.</p> <p>Participants in long‐term analysis (3, 6 months), I1: 7–10; I2: 10–14 (table 3).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing (mean)</p> <p>I1: 10.5 days; I2: 12.4 days, reported P &lt; 0.05.</p> <p>Wound infection (rate)</p> <p>I1: 3/20; I2: 8/20.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain (mean): I1: 4.1; I2: 4.6.</p> <p>Scar quality (Vancouver Scar Scale): I1: 4; I2: 7, reported P &gt; 0.05.</p> <p>Patient satisfaction (comfortable, mild discomfort, discomfort): I1: 14, 2, 4; I2: 10, 4, 6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I1: 78; I2: 76.</p> <p>Mean age: I: 41.9 (SD 16.9) years; I2: 41.3 (SD 14.5) years.</p> <p>Aetiology:</p> <p><i>Flame:</i> I1: 70; I2: 60<i>.</i> <br/><i>Scald:</i> I1: 4; I2: 3. </p> <p>% TBSA burned (median (IQR): I1: 9.8 (5.0–19.4); I2: 9.3 (4.5–17.0).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 179.</p> <p>After randomisation: I1: 90; I2: 89.</p> <p>After postrandomisation exclusion: I1: 78; I2: 76.</p> <p>Participants in short‐term analysis (primary analysis): I1: 77; I2: 73.</p> <p>Participants in long‐term analysis (6 months) I1: 60; I2: 50)</p> <p>(12 months): I1: 50; I2: 46.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to wound partial healing: (survival analysis, all participants), reported P = 0.71. </p> <p>Median days (25–75th percentile) to healing (&gt; 90%) in wounds without surgery: I1: 11.0 (7.0–15.0); I2: 9.0 (5.0–17.75), reported P = 0.17. </p> <p>Mean time to wound healing: I1: 14.3 (SD 14.5) days; I2: 21.4 (SD 37.6) days (data delivered upon request). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for surgery: I1: 13/77; I2: 15/73, reported P = 0.565, OR 0.8 (95% CI 0.3 to 1.8). </p> <p>Pain (background pain, before wound care, mean): I1: 0.6 (SEM 0.2); I2: 1.2 (SEM 0.4), reported P = 0.16. </p> <p>Pain (procedural pain, during wound care): I1: 1.3 (SEM 0.3); I2: 1.6 (SEM 0.5), reported P = 0.59. </p> <p>Scar quality at 12 months (Patient and Observer Scar Assessment Scale) (median):</p> <p>(patient report): I1: 1.2 (25–75th percentile 1.0–2.2); I2: 1.0 (25–75th percentile 1.0–1.8), reported P = 0.42; </p> <p>(observer report): I1: 1.4 (25–75th percentile 1.2–1.8); I2: 1.4 (25–75th percentile 1.2–1.6), reported P = 0.17. </p> <p>(mean):</p> <p>(patient report) I1: 2.0 (SD 1.5); I2: 1.8 (SD 1.5);</p> <p>(observer report) I1: 1.7 (SD 0.9); I2: 1.6 (SD 0.8) (delivered upon request).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants I: 27; C: 16.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 46.</p> <p>After randomisation: I: 27; C: 19, after postrandomisation exclusion: I: 27; C: 16.</p> <p>Participants in short‐term analysis: not documented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing (mean days: I: 11 (SD 2); C: 15 (SD 3), reported P &lt; 0.0001. </p> <p>Number of participants with complete wound healing within 14 days: I: 27/27; C: 3/16, P value not reported. </p> <p>Wound infection: bacterial colonisation in all participants; absence of signs of systemic infection. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain (mean pain reduction scores): I: 2.7 (SD 1.35); C: 2.00 (SD 0.89), reported P interaction intervention by change pain = 0.072. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: 25 (within‐patient comparison): 15 superficial degree II burns; 10 deep degree II burns. </p> <p>% TBSA burned (mean): 45.1 (SD 25.2) (superficial degree II burns); 54.9 (SD 31.7) (deep degree II burns). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 25.</p> <p>After randomisation: 25.</p> <p>Participants in short‐term analysis: 25.</p> <p>Participants in long‐term analysis: no numbers provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to wound healing (mean days)</p> <p>Superficial degree II burns: I: 8.6 (SD 1.12); C: 8.67 (SD 1.18) (reported P = 0.855).</p> <p>Deep degree II burns: I: 15.80 (SD 1.55); C: 18.20 (SD 1.55), reported P = 0.005.</p> <p>Infection:</p> <p>Superficial degree II burns:</p> <p>I: 1/15; C: 1/15, P &gt; 0.05</p> <p>Deep degree II burns:</p> <p>I: 1/10; C: 1/10, reported P &gt; 0.05.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain (mean VAS)</p> <p>Superficial degree II burns:</p> <p>I: 2.73 (SD 0.70); C: 1.53 (SD 0.83), reported P = 0.000.</p> <p>Deep degree II burns:</p> <p>I: 5.70 (SD 0.95); C: 2.70 (SD 0.48), reported P = 0.000.</p> <p>Scar quality at 3 months (mean Vancouver Scar Scale)</p> <p>Superficial degree II burns:</p> <p>I: 0.80 (SD 0.77); C: 0.80 (SD 0.77), reported P = 1.000.</p> <p>Deep degree II burns: I: 3.50 (SD 0.71); C: 5.50 (SD 1.08), reported P = 0.000.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>C: comparator; CI: confidence interval; I: intervention; IQR: interquartile range; MEBO: Moist Exposed Burn Ointment; OR: odds ratio; PB: postburn; SD: standard deviation; SE: standard error; SEM: standard error of the mean; TBSA: total body surface area. </p> </div> </div> <section id="CD008058-sec-0063"> <h4 class="title">Comparison 1: topical antimicrobial agent compared with topical non‐antimicrobial agent </h4> <p>Three studies including 139 people compared topical antimicrobial agents with topical non‐antimicrobial agents (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>). The antimicrobials agents included SSD and Aquacel‐Ag and were compared with MEBO or saline‐soaked dressings. </p> <p>There is moderate to very low‐certainty evidence that antimicrobial agents and non‐antimicrobial agents are similar in time to wound healing and wound infection (<a href="./full#CD008058-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD008058-sec-0064"> <h5 class="title">Primary outcomes</h5> <section id="CD008058-sec-0065"> <h6 class="title">Time to complete wound healing</h6> <p>There is mixed‐certainty evidence that there is no clear difference in time to complete wound healing (no overall effect size available). One study revealed moderate </p> <p>‐certainty evidence. suggesting that SSD and MEBO probably make little or no difference in time to complete wound healing (reported HR 0.84, 95% CI 0.78 to 1.85; 1 study, 39 participants; downgraded once for imprecision). Another study presented similar results on mean time to wound healing in a three‐group comparison of Aquacel‐Ag with MEBO or with saline‐soaked dressings, each applied in 20 patients (mean days to wound healing 10.05 (SD 2.3) versus 10.35 (SD 2.8) and 12.05 (SD 2.4), no overall effect estimate available, 1 study, 60 participants; downgraded once for risk of bias and once for imprecision (<a href="./full#CD008058-tbl-0001">summary of findings Table 1</a>); (<a href="./references#CD008058-fig-0004" title="">Analysis 1.1</a>). </p> <p><b>Proportion of wounds completely healed</b> </p> <p>There is low‐certainty evidence that SSD and MEBO may make little or no difference to the proportion of wounds completely healed within 10 days (RR 0.94, 95% CI 0.68 to 1.29; 1 study, 39 participants; downgraded twice for imprecision; <a href="./references#CD008058-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD008058-sec-0066"> <h6 class="title">Change in wound surface area over time or partial healing</h6> <p>No studies measured change in wound surface area over time or partial healing.</p> </section> <section id="CD008058-sec-0067"> <h6 class="title">Wound infection</h6> <p>We are uncertain whether there is a difference in wound infection between a topical antimicrobial (Aquacel‐Ag) and a non‐antimicrobial agent (MEBO) (RR 0.38, 95% CI 0.12 to 1.21; 1 study, 40 participants; very low‐certainty evidence, downgraded once for risk of bias and twice for imprecision; <a href="./references#CD008058-fig-0006" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD008058-sec-0068"> <h5 class="title">Secondary outcomes</h5> <section id="CD008058-sec-0069"> <h6 class="title">Proportion of facial burns requiring surgery</h6> <p>One study assessed surgery. No participant in either group received surgery, thus no treatment effect was estimable (1 study, 37 participants; <a href="./references#CD008058-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD008058-sec-0070"> <h6 class="title">Scar quality</h6> <p>There is low‐certainty evidence that topical antimicrobial agents or topical non‐antimicrobial agents may make little or no difference to scar quality (RR 1.19, 95% CI 0.87 to 1.61; 1 study (2 comparisons), 60 participants; I<sup>2</sup> = 29%; low‐certainty, evidence downgraded once for imprecision and once for risk of bias; <a href="./references#CD008058-fig-0008" title="">Analysis 1.5</a>). </p> <p><a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a> addressed scar quality but provided incomplete results and could not be included in the analysis. </p> </section> <section id="CD008058-sec-0071"> <h6 class="title">Pain</h6> <p>Two studies assessed and incompletely reported pain (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>). </p> </section> <section id="CD008058-sec-0072"> <h6 class="title">Patient satisfaction</h6> <p>Topical antimicrobial agents (i.e. hydrofibre Aquacel Ag) may result in slightly higher participant satisfaction, compared with non‐antimicrobial agents (including MEBO) and saline‐soaked dressings) (RR excellent/comfortable patient satisfaction 1.55, 95% CI 1.06 to 2.27; 2 studies (3 comparisons), 100 participants; I<sup>2</sup> = 64%; low‐certainty evidence, downgraded once for imprecision and once for risk of bias; <a href="./references#CD008058-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD008058-sec-0073"> <h6 class="title">Adverse effects</h6> <p>None of the studies addressed adverse effects.</p> </section> <section id="CD008058-sec-0074"> <h6 class="title">Quality of life</h6> <p>None of the studies addressed quality of life.</p> </section> <section id="CD008058-sec-0075"> <h6 class="title">Length of hospital stay</h6> <p>None of the studies addressed LOS.</p> </section> </section> </section> <section id="CD008058-sec-0076"> <h4 class="title">Comparison 2: topical antimicrobial agents compared with other topical antimicrobial agents </h4> <p>Two studies compared topical antimicrobial agents with another topical antimicrobial agent in 169 participants (<a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>). The antimicrobial agents included CN‐SSD versus SSD and mafenide acetate cream and gentamicin via iontophoresis versus usual care (mafenide acetate cream). </p> <p>There is low‐certainty evidence that antimicrobial agents are similar in time to wound healing and very low‐certainty evidence that they are similar in wound infection (<a href="./full#CD008058-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD008058-sec-0077"> <h5 class="title">Primary outcomes</h5> <section id="CD008058-sec-0078"> <h6 class="title">Time to complete wound healing</h6> <p>No studies measured time to complete wound healing.</p> <p><b>Proportion of wounds completely healed.</b> </p> <p>No studies measured the proportion of wounds completely healed.</p> </section> <section id="CD008058-sec-0079"> <h6 class="title">Change in wound surface area over time or partial healing</h6> <p>CN‐SSD and SSD may make little or no difference in time to complete wound healing (low‐certainty evidence, downgraded once for imprecision and once for risk of bias). <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a> reported time to event analysis on time to more than 90% wound healing and found no differences between CN‐SSD (antimicrobial agent 1) versus SSD (antimicrobial agent 2) (survival analysis, Kaplan Meier; 129 participants; reported P = 0.71 (log‐rank test)), and provided mean time to wound healing (MD –7.10 days, 95% CI –16.43 to 2.23; 1 study, 142 participants; <a href="./references#CD008058-fig-0010" title="">Analysis 2.1</a>). </p> </section> <section id="CD008058-sec-0080"> <h6 class="title">Wound infection</h6> <p>We are uncertain whether using several antimicrobial agents (mafenide acetate cream and gentamicin via iontophoresis versus usual care (mafenide acetate cream) reduces wound infection (infection, resulting in chondritis (inflammation of cartilage) (<a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>)), as the certainty of evidence is very low (RR 0.73, 95% CI 0.46 to 1.17; downgraded twice for risk of bias and twice for imprecision; <a href="./references#CD008058-fig-0011" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD008058-sec-0081"> <h5 class="title">Secondary outcomes</h5> <section id="CD008058-sec-0082"> <h6 class="title">Proportion of facial burns requiring surgery</h6> <p>There is low‐certainty evidence that there is no clear difference between topical antimicrobial agents in the proportion of facial burns requiring surgery (RR 0.82, 95% CI 0.42 to 1.61; 1 study, 150 participants; downgraded once for risk of bias and once for imprecision; <a href="./references#CD008058-fig-0012" title="">Analysis 2.3</a>). </p> </section> <section id="CD008058-sec-0083"> <h6 class="title">Scar quality</h6> <p>There is low‐certainty evidence that there is little or no difference between topical antimicrobial agents in scar quality as reported by the participant (MD 0.20 on a scale from 1‐10, 95% CI –0.40 to 0.80; 1 study, 85 participants; <a href="./references#CD008058-fig-0014" title="">Analysis 2.5</a>) and by the care provider/observer (MD 0.10, 95% CI –0.24 to 0.44; 1 study, 96 participants; <a href="./references#CD008058-fig-0015" title="">Analysis 2.6</a>). The evidence was downgraded once for risk of bias and once for imprecision. </p> </section> <section id="CD008058-sec-0084"> <h6 class="title">Pain</h6> <p>There is low‐certainty evidence that there is little or no difference between topical antimicrobial agents in pain, as assessed on a 0‐10 scale with the visual analogue thermometer, in procedural pain (MD –0.30, 95% CI –1.44 to 0.84; 1 study, 150 participants; <a href="./references#CD008058-fig-0016" title="">Analysis 2.7</a>); or background pain (MD –0.60, 95% CI –1.48 to 0.28; 1 study, 150 participants; <a href="./references#CD008058-fig-0017" title="">Analysis 2.8</a>). The evidence was downgraded once for risk of bias and once for imprecision. </p> </section> <section id="CD008058-sec-0085"> <h6 class="title">Patient satisfaction</h6> <p>Neither study reported patient satisfaction.</p> </section> <section id="CD008058-sec-0086"> <h6 class="title">Adverse effects</h6> <p>It is uncertain whether gentamicin iontophoresis reduces adverse events (appearance of gentamicin‐resistant organisms) as the certainty of the evidence is very low (downgraded twice for risk of bias and twice for imprecision) (2/7 versus 0/8; RR 5.63, 95% CI 0.31 to 100.52; 1 study, 15 participants; <a href="./references#CD008058-fig-0018" title="">Analysis 2.9</a>). </p> </section> <section id="CD008058-sec-0087"> <h6 class="title">Quality of life</h6> <p>Neither study reported quality of life.</p> </section> <section id="CD008058-sec-0088"> <h6 class="title">Length of hospital stay</h6> <p>It is uncertain whether gentamicin iontophoresis reduces LOS as the certainty of the evidence is very low (downgraded twice for risk of bias and twice for imprecision) (MD –12.00 days, 95% CI –18.20 to –5.80; 1 study, 15 participants; <a href="./references#CD008058-fig-0019" title="">Analysis 2.10</a>); however, there are no differences if differences in burn size were taken into account. </p> </section> </section> </section> <section id="CD008058-sec-0089"> <h4 class="title">Comparison 3: skin substitutes compared with topical antimicrobial agents</h4> <p>Four trials of 90 people, including 115 wounds, compared skin substitutes with topical antimicrobial agents. Three studies randomised and compared 65 participants, the fourth study randomised and compared two facial wounds within 25 participants (<a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>). </p> <p>Four studies compared a skin substitute (a bioengineered skin substitute (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>), an allograft (<a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>), or a xenograft (<a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>) with an topical antimicrobial agent (bacitracin (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>), SSD (<a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>), Physiotulle Ag (<a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>), or an unspecified antibacterial ointment (<a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>)). </p> <p>There is low‐certainty evidence on the effects of skin substitutes versus topical antimicrobial agents in time to wound healing and very low‐certainty evidence on wound infection (<a href="./full#CD008058-tbl-0003">summary of findings Table 3</a>). </p> <section id="CD008058-sec-0090"> <h5 class="title">Primary outcome</h5> <section id="CD008058-sec-0091"> <h6 class="title">Time to complete wound healing</h6> <p>One study reported time to complete wound healing (<a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>), but they did not use the appropriate statistical method (i.e. survival methods for time to event data). Data from <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a> could not be used because of lack of estimate of variance. The authors reported the median time to re‐epithelialisation, which was significantly less in the allograft group (10.5 days; 5 participants) compared with the SSD group (12.4 days; 5 participants; reported P &lt; 0.05). </p> <p><b>Proportion of wounds completely healed</b> </p> <p>None of the studies reported on the proportion completely healed.</p> </section> <section id="CD008058-sec-0092"> <h6 class="title">Change in wound surface area over time or partial healing</h6> <p>Three studies reported time to partial wound healing (time to 95% wound healing (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>); time to 90% wound healing (<a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>)); but used no appropriate statistical method (i.e. survival methods for time to event data). Due to differences in study design (unit of analysis (participant versus wounds)) and data presentation (mean versus median), no overall effect estimate was calculated. </p> <p>Because of concerns about possible patient overlap between two studies (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>), only data from the most recent study with the largest sample size were included in the analysis. </p> <p>There is low‐certainty evidence that a skin substitute may slightly reduce mean time to partial wound healing compared with the antibacterial ointment group (MD –6.00 days, 95% CI –8.69 to –3.31; 1 study, 34 participants; downgraded once for risk of bias and once for imprecision; <a href="./references#CD008058-fig-0020" title="">Analysis 3.1</a>). </p> <p>Data from <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> could not be incorporated into the analysis because of a comparison of wounds within patients. <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> reported a mean time to wound healing in both superficial and deep partial thickness burns; mean time to wound healing was lower after skin substitute treatment in deep dermal burns (MD –2.40 days, 95% CI –3.76 to –1.04; 1 study, 10 participants (20 wounds); <a href="./references#CD008058-fig-0021" title="">Analysis 3.2</a>); but there were no differences in superficial burns (MD –0.07 days, 95% CI –0.89 to 0.75; 1 study, 15 participants (30 wounds); <a href="./references#CD008058-fig-0021" title="">Analysis 3.2</a>). </p> </section> <section id="CD008058-sec-0093"> <h6 class="title">Wound infection</h6> <p>We are uncertain whether skin substitutes reduce wound infection as the certainty of the evidence is very low. Very low‐certainty evidence in combination with non‐estimable effects results in inconclusive effects of skin substitutes versus topical antimicrobial agents (<a href="./references#CD008058-fig-0022" title="">Analysis 3.3</a>, downgraded once for risk of bias and twice for imprecision). Three studies reported wound infection. In two studies, none of the participants showed signs of infection (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a> (data on skin substitute only)). <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> reported "one infection in each group", probably one infected wound in each group. </p> </section> </section> <section id="CD008058-sec-0094"> <h5 class="title">Secondary outcomes</h5> <section id="CD008058-sec-0095"> <h6 class="title">Proportion of facial burns requiring surgery</h6> <p>None of the studies reported proportion of facial burns requiring surgery.</p> </section> <section id="CD008058-sec-0096"> <h6 class="title">Scar quality</h6> <p>It is uncertain whether skin substitutes improve scar quality as the certainty of the evidence is low to very low. In addition, incomparable data presentation resulted in an inconclusive outcome. Scar quality was a reported outcome in two studies and assessed as the proportion hypertrophic scar formation six months postburn (<a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>), or with the Vancouver Scar Scale (VSS) three months postburn in wounds within patients (<a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>). Very low‐certainty evidence from <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a> showed that the skin substitute group may have little to no reduction in the prevalence of hypertrophic scars compared with the antimicrobial group (RR 0.20, 95% CI 0.01 to 3.35; 1 study, 10 participants; <a href="./references#CD008058-fig-0023" title="">Analysis 3.4</a>, downgraded once for risk of bias and twice for imprecision). It is uncertain whether xenografts reduce scar morbidity. <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> reported lower mean VSS scores after skin substitute treatment in deep dermal burns (MD –2.00 on a scale from 0‐15, 95% CI –2.80 to –1.20; 1 study, 10 participants (20 wounds); <a href="./references#CD008058-fig-0024" title="">Analysis 3.5</a>), but no differences in superficial burns (MD 0.00, 95% CI –0.55 to 0.55; 1 study, 15 participants (30 wounds); <a href="./references#CD008058-fig-0024" title="">Analysis 3.5</a>) (low‐certainty evidence, downgraded once for risk of bias and once for imprecision). </p> </section> <section id="CD008058-sec-0097"> <h6 class="title">Pain</h6> <p>Three studies reported pain (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>); the studies of Demling assessed both procedural pain and background pain (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>). </p> <p>We are uncertain whether skin substitutes in general reduce pain as the certainty of the evidence is very low (downgraded once for risk of bias, once for inconsistency and once for imprecision). </p> <p>Individual studies revealed inconclusive results based on low‐certainty evidence. In <a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a> and <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>, pain scores were significantly lower in all comparisons between skin substitute groups (TransCyte) versus the topical treatment groups. Because of concerns about possible patient overlap between <a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a> and <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>, the summary effect estimate was calculated based on data from the most recent Demling study only (<a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>). Low‐certainty evidence shows that skin substitutes may slightly reduce procedural pain (MD –4.00 on a 0‐10 scale, 95% CI –5.05 to –2.95; 1 study, 34 participants; <a href="./references#CD008058-fig-0025" title="">Analysis 3.6</a>) and background pain (MD –2.00, 95% CI –3.05 to –0.95; 1 study, 34 participants; <a href="./references#CD008058-fig-0025" title="">Analysis 3.6</a>). In contrast, low‐certainty evidence from <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> indicated that skin substitutes (biological dressing (porcine Xenoderm)), compared with antimicrobial agents (Physiotulle Ag (Coloplast)) might slightly increase pain in superficial burns (MD 1.20 on a 0‐10 scale, 95% CI 0.65 to 1.75; 1 study, 15 participants (30 wounds); <a href="./references#CD008058-fig-0027" title="">Analysis 3.8</a>), as well as deep partial thickness burns (MD 3.00, 95% CI 2.34 to 3.66; 1 study, 10 participants (20 wounds); <a href="./references#CD008058-fig-0027" title="">Analysis 3.8</a>). </p> </section> <section id="CD008058-sec-0098"> <h6 class="title">Patient satisfaction</h6> <p>None of the studies reported patient satisfaction.</p> </section> <section id="CD008058-sec-0099"> <h6 class="title">Adverse effects of treatment</h6> <p>It is uncertain whether skin substitutes reduce adverse effects of treatment as the certainty of the evidence is very low (downgraded once for risk of bias, and twice for imprecision). One study reported that one participant in the intervention group had a localised integration of the biological dressing, which was removed by two repeated dermabrasion manoeuvres (<a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>). After these manoeuvres, no more visible allograft remnants remained. </p> </section> <section id="CD008058-sec-0100"> <h6 class="title">Quality of life</h6> <p>None of the studies reported quality of life.</p> </section> <section id="CD008058-sec-0101"> <h6 class="title">Length of hospital stay</h6> <p>It is uncertain whether skin substitutes reduce LOS as the certainty of the evidence is very low (selective data reporting in <a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>) (MD –2.00 days, 95% CI –2.98 to –1.02; 1 study, 10 participants; downgraded once for risk of bias, and twice for imprecision; <a href="./references#CD008058-fig-0028" title="">Analysis 3.9</a>). </p> </section> </section> </section> <section id="CD008058-sec-0102"> <h4 class="title">Comparison 4: miscellaneous treatment compared with miscellaneous treatment</h4> <p>Four studies compared a variety of miscellaneous topical treatments in 123 participants and 148 wounds including <a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a> (comparison growth hormone therapy (rhGM CS) versus a placebo hydrogel); <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> (comparison MEBO versus saline); <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a> (comparison enzymatic debridement versus topical antimicrobial agent in wounds within participants); and <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a> (comparison alternative topical agent versus MEBO). </p> <p>Low to very low‐certainty evidence shows mainly inconclusive effectiveness of these treatments in time to wound healing and infection (<a href="./full#CD008058-tbl-0004">summary of findings Table 4</a>). </p> <section id="CD008058-sec-0103"> <h5 class="title">Primary outcomes</h5> <section id="CD008058-sec-0104"> <h6 class="title">Time to complete wound healing and proportion of wounds completely healed</h6> <p>Four studies reported time to complete wound healing, one based on a comparison of wounds within patients (<a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>). <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a> also reported the proportion of participants who were completely healed at 14 days. </p> <p>We did not aim to calculate overall effect estimates because of the heterogeneity of interventions. Individual studies showed low to very low‐certainty evidence for effects of interventions, downgraded once for risk of bias and once or twice for imprecision. </p> <p>MEBO may slightly reduce time to wound healing compared with saline‐soaked dressing (MD –1.7 days, 95% CI –3.32 to –0.08; 1 study, 40 participants; <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>; <a href="./references#CD008058-fig-0029" title="">Analysis 4.1</a>). <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a> reported similar time to complete epithelialisation in 10 participants with two wounds each (mean: 37.6 days after enzymatic debridement versus 37.4 days after antimicrobial agent; reported p‐value not shown because of the use of inappropriate analyses not reflecting the paired character of the data). This is low‐certainty evidence downgraded once for risk of bias and once for imprecision in each case. </p> <p>A cream containing Helix Aspersa may slightly increase the proportion of wounds completely healed at 14 days compared with MEBO (RR 4.77, 95% CI 1.87 to 12.15; 1 study, 43 participants; <a href="./references#CD008058-fig-0030" title="">Analysis 4.2</a>). This is low‐certainty evidence downgraded once for risk of bias and once for imprecision. </p> </section> <section id="CD008058-sec-0105"> <h6 class="title">Change in wound surface area over time or partial healing</h6> <p>One study measured change in wound surface area over time or partial healing, by assessing percentage wound healing at 3, 5, 7 and 14 days after treatment (<a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a>). Reporting of results was limited to the reported P &lt; 0.01 difference at days 5, 7 and 14; no data were reported; no GRADE assessment was possible. </p> </section> <section id="CD008058-sec-0106"> <h6 class="title">Wound infection</h6> <p>One study addressed wound infection. In the absence of clinical infections in both groups, no effect estimate was calculated (<a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>; <a href="./references#CD008058-fig-0031" title="">Analysis 4.3</a>). The certainty of evidence is very low (downgraded once for risk of bias and twice for serious imprecision). <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a> planned to assess wound infection but did not report outcomes addressing wound infections. </p> </section> </section> <section id="CD008058-sec-0107"> <h5 class="title">Secondary outcomes</h5> <section id="CD008058-sec-0108"> <h6 class="title">Proportion of facial burns requiring surgery</h6> <p>None of the studies reported proportion of facial burns requiring surgery.</p> </section> <section id="CD008058-sec-0109"> <h6 class="title">Scar quality</h6> <p>MEBO may make little or no difference to scar quality (quality of healing) compared with saline soaked dressings (RR excellent scar quality 1.45, 95% CI 0.92 to 2.29; 1 study, 40 participants; low‐certainty evidence downgraded once for risk of bias and once for imprecision; <a href="./references#CD008058-fig-0032" title="">Analysis 4.4</a>) (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>). <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a> planned to assess scar quality but did not report outcomes addressing scar quality. </p> </section> <section id="CD008058-sec-0110"> <h6 class="title">Pain</h6> <p>A cream containing Helix Aspersa may make little or no difference to pain, compared with MEBO (MD 0.70 points on a 0 to 10 scale, 95% CI 0.03 to 1.37; 1 study, 43 participants; low‐certainty evidence downgraded once for risk of bias and once for imprecision; <a href="./references#CD008058-fig-0033" title="">Analysis 4.5</a>) (<a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>). The data reported by <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> were insufficient for analysis. They graphically presented pain scores per treatment group at days one or two postburn and from day three onwards. In addition, <a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> reported on participants treated with MEBO (comparator intervention 1) as "…patients felt the least pain on the first two days (mean 3.1 on a 0‐10 scale, SD [standard deviation] 1.9) and on day 3 onwards (mean 1.3, SD=1.5)", but data on other groups were not reported. <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a> planned to assess pain but did not report outcomes addressing pain. </p> </section> <section id="CD008058-sec-0111"> <h6 class="title">Patient satisfaction</h6> <p>We are uncertain whether MEBO improves patient satisfaction compared with saline‐soaked dressings (excellent patient satisfaction; RR 6.00, 95% CI 1.54 to 23.44; 1 study, 40 participants; very low‐certainty evidence, downgraded once for risk of bias and twice for imprecision; <a href="./references#CD008058-fig-0034" title="">Analysis 4.6</a>) (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>). </p> </section> <section id="CD008058-sec-0112"> <h6 class="title">Adverse effects</h6> <p>None of the studies reported adverse effects.</p> </section> <section id="CD008058-sec-0113"> <h6 class="title">Quality of life</h6> <p>None of the studies reported quality of life.</p> </section> <section id="CD008058-sec-0114"> <h6 class="title">Length of hospital stay</h6> <p>None of the studies reported LOS.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008058-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008058-sec-0115"></div> <section id="CD008058-sec-0116"> <h3 class="title" id="CD008058-sec-0116">Summary of main results</h3> <p>We included 12 RCTs in this review that evaluated the effect of a variety of topical interventions for facial burns. These trials enrolled 507 participants, mainly adults, admitted in specialised burn centres after recent burn injuries. </p> <p>Using GRADE, we assessed the certainty of the evidence, which is low to very low for almost all primary outcomes in the four comparisons. The reasons for these judgements are outlined in the 'Summary of findings' tables for the included comparisons. </p> <p>The variety of topical interventions evaluated, the differences in unit of analyses and outcome measures between studies, and incomplete data presentation hampered pooling of data. </p> <section id="CD008058-sec-0117"> <h4 class="title">Wound healing</h4> <p>Wound healing was variously measured and reported including: time to complete wound healing time to 90% wound healing, or change in wounds and percentage of wound healed during follow‐up. Most studies reported time to wound healing, but only two studies used survival methods (the appropriate approach to statistical analysis of time to event data) (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>; <a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>). </p> <p>The comparison between topical antimicrobial and non‐antimicrobial agents revealed moderate to low‐certainty evidence, indicating no or little difference in time to wound healing between topical agents. </p> <p>Comparing between topical antimicrobial agents showed that topical antimicrobial agents may make no difference in time to wound healing as the evidence is low certainty. </p> <p>The comparison between skin substitutes and topical antimicrobial agents showed low‐certainty evidence that a skin substitute (TransCyte) may slightly reduce time to wound healing. </p> <p>Finally, when comparing miscellaneous treatments, single studies showed low or very low‐certainty effects of interventions. MEBO may slightly reduce time to wound healing, compared with saline‐soaked dressing. A cream containing Helix Aspersa (Elicina) may slightly increase the proportion completely healed at 14 days compared with MEBO. </p> </section> <section id="CD008058-sec-0118"> <h4 class="title">Infection</h4> <p>There is no, or inconclusive, evidence that topical therapies may reduce infections in people with facial burns. The certainty of evidence is very low, derived from four comparisons including data from nine studies. </p> <p>Seven studies addressed wound infection as a negative outcome. The lack of events in studies, in combination with incomplete reports hampered any conclusions on effectiveness of treatments regarding infections. In addition, two studies assessed wound colonization as a proxy for wound infection and thus did not contribute to the body of evidence. Overall, these data were insufficient to support any definite conclusions. </p> </section> <section id="CD008058-sec-0119"> <h4 class="title">Secondary outcomes</h4> <p>Except for quality of life, at least one study addressed all other secondary outcomes (proportion of facial burns requiring surgery, scar quality, pain, adverse effects of treatment, patient satisfaction and LOS). Pain (eight studies) and scar quality (six studies) were the most frequently addressed outcomes. </p> <p>We chose not to include the secondary outcomes in the 'Summary of findings' tables, because of the overall low to very low‐certainty of evidence in combination with the sparse and scattered information in the four comparisons. </p> <p>Low‐certainty evidence from single studies on skin substitutes versus topical antimicrobial agents shows inconsistent results. Skin substitutes may slightly decrease pain (TransCyte) or slightly increase pain (xenograft). Pain was assessed using a visual analogue scale. </p> <p>In addition, low‐certainty evidence indicates that MEBO may slightly improve patient satisfaction, compared with saline‐soaked dressings, as assessed on a 4‐point scale. </p> <p>Other comparisons indicate no or little effects based on low‐certainty evidence or very low‐certainty evidence only. This impedes any conclusion on effects of topical agents in facial burns. </p> <p>Because the certainty of evidence is low to very low, our findings barely contribute to the body of evidence that favours antimicrobial agents above non‐antimicrobial agents. </p> <p>One study addressed the need for reconstructive surgery (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>); none of the participants needed surgery in the short follow‐up period (six months). Future studies addressing the need for reconstructive surgery should probably include a longer follow‐up to include all relevant events. Reconstructive surgery can be divided into urgent, essential and desirable procedures. The urgent and essential procedures might be performed within a six‐month follow‐up period, but the desirable procedure is usually postponed until scars have fully matured. This maturation can take one year or longer (<a href="./references#CD008058-bbs2-0034" title="BarretJP . ABC of burns: burns reconstruction. BMJ2004;329(7460):274-6.">Barret 2004</a>). Therefore, differences in the need for reconstructive surgery between intervention and control group might appear in a later phase. </p> <p>A few studies reported on adverse events, again not providing robust evidence.</p> </section> </section> <section id="CD008058-sec-0120"> <h3 class="title" id="CD008058-sec-0120">Overall completeness and applicability of evidence</h3> <p>The objective of this review was to assess the effectiveness of topical interventions on wound healing in people with facial burns of any depth. All topical interventions were eligible for inclusion, and we identified multiple different interventions. Participants were recruited in burn centres from four continents. Studies included most outcome measures, except quality of life. The applicability of evidence might be restricted to specialised burn centres in high‐income countries, because of the relatively high costs of skin substitutes and wound dressings. In addition, part of the evidence stems from older studies (five RCTs were published before 2006), which could limit the applicability of the evidence because some topical interventions are probably less frequently applied nowadays. For instance, the application of iontophoresis in combination with an antimicrobial agent has not been described since <a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>, as far as we know. However, all topical interventions are still available on the market, and seem to be applied in global burn care. </p> </section> <section id="CD008058-sec-0121"> <h3 class="title" id="CD008058-sec-0121">Quality of the evidence</h3> <p>The certainty of evidence combined in this review is mainly low to very low and insufficient to allow definite conclusions to be drawn. </p> <section id="CD008058-sec-0122"> <h4 class="title">Limitations in study design</h4> <p>The substantial increase in the number of included RCTs did not result in high‐certainty evidence for the included comparisons. The RCTs added in this update had similar high risks of bias as the studies included in the original review. In addition, most newly included RCTs lacked precision, because of small sample sizes and absent sample size calculations. One RCT with a sample size calculation did not reach the necessary requirements (<a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>). As a result of this, the evidence in all comparisons but one was downgraded by two levels because of high risk of bias and imprecision. </p> <p>The high risk of bias was mostly related to a high risk of performance and detection bias due to absent blinding of participants, providers and, to a lesser extent, outcome assessors. Blinding of participants and care providers is not easy in studies that compare topical interventions, but outcome assessors could have been blinded. Despite this possibility, only three out of twelve studies reported blinding of outcome assessors for all outcomes). Selection bias was a second source of bias. </p> <p>Adequate sequence generation and allocation concealment were done in only a minority of studies (maximum three). </p> </section> <section id="CD008058-sec-0123"> <h4 class="title">Imprecision of results</h4> <p>Imprecision remained a main issue in the update of the review, with seven small‐sized studies, of maximal 39 participants and low event rates. Thus, effect estimates could often not be calculated, or with wide CIs only. While pooling data from small trials could increase statistical power and give a more precise overall estimate of effect size, the studies in this review only partly compared similar interventions and outcome measures. In addition, the different unit of analysis in included studies further hampered data synthesis/the pooling of studies included in the update (<a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>), data from these studies could not be included in the calculation of pooled effect estimates. </p> </section> <section id="CD008058-sec-0124"> <h4 class="title">Unexplained heterogeneity or inconsistency</h4> <p>Inconsistency could barely be addressed because of the limited evidence available. In our 'Summary of findings' tables, seven of the ten effect estimates were based on one study only. </p> </section> <section id="CD008058-sec-0125"> <h4 class="title">Indirectness of evidence</h4> <p>Issues related to indirectness bias are probably limited; all studies included the target population and the primary outcome measures. </p> </section> <section id="CD008058-sec-0126"> <h4 class="title">Publication bias</h4> <p>We could not assess publication bias with a Begg funnel plot or an Egger test, because the included studies were heterogeneous and sometimes poorly reported. However, included RCTs did not show clear indications of publication bias, for instance there was no sign of any selection of studies with large effects only. </p> </section> </section> <section id="CD008058-sec-0127"> <h3 class="title" id="CD008058-sec-0127">Potential biases in the review process</h3> <p>Potential bias in the review process might have arisen as a result of the minimal response to our queries from authors of the eligible studies. The review authors tried to contact study authors by email in an attempt to retrieve all possible data to assess the studies thoroughly. Despite issuing a reminder, we received only three replies from <a href="./references#CD008058-bbs2-0015" title="BranskiLK , HerndonDN , CelisMM , NorburyWB , MastersOE , JeschkeMG . Amnion in the treatment of pediatric partial-thickness facial burns. Burns2008;34(3):393-9. [DOI: 10.1016/j.burns.2007.06.007]BranskiLK , HerndonDN , NorburyWB , CelisM , MastersOE , JeschkeMG . Amnion in the treatment of pediatric facial partial-thickness burns. Journal of Burn Care and Research2007;28(2):S106. ">Branski 2008</a>, <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>, and <a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a>, with answers to our questions. As a result of those answers, we excluded the <a href="./references#CD008058-bbs2-0015" title="BranskiLK , HerndonDN , CelisMM , NorburyWB , MastersOE , JeschkeMG . Amnion in the treatment of pediatric partial-thickness facial burns. Burns2008;34(3):393-9. [DOI: 10.1016/j.burns.2007.06.007]BranskiLK , HerndonDN , NorburyWB , CelisM , MastersOE , JeschkeMG . Amnion in the treatment of pediatric facial partial-thickness burns. Journal of Burn Care and Research2007;28(2):S106. ">Branski 2008</a> study as sequence generation and allocation concealment were inadequate and, therefore, we judged that it was not an RCT. Eight other studies scored unclear on these items, but as additional information was not provided, they were included. To prevent potential bias due to the inclusion of a study from our review group, a third person not involved in this study was added to provide independent assessment of risk of bias and data extraction. Another potential bias might have occurred due to a possible patient overlap between <a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a> and <a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>. Both studies were performed in the same hospital, and did not provide inclusion periods. Therefore, we were unable to confirm whether there was a patient overlap. To prevent any overlap in data, we only included data from the most recent study in the analyses and in the 'Summary of findings' tables (<a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>). </p> </section> <section id="CD008058-sec-0128"> <h3 class="title" id="CD008058-sec-0128">Agreements and disagreements with other studies or reviews</h3> <p>In general, the results of this updated review are in accordance with other systematic reviews on topical therapy in burns of any location (<a href="./references#CD008058-bbs2-0069" title="JullAB , CullumN , DumvilleJC , WestbyMJ , DeshpandeS , WalkerN . Honey as a topical treatment for wounds. Cochrane Database of Systematic Reviews2015, Issue 3. Art. No: CD005083. [DOI: 10.1002/14651858.CD005083.pub4]">Jull 2015</a>; <a href="./references#CD008058-bbs2-0093" title="WasiakJ , ClelandH , CampbellF , SpinksA . Dressings for superficial and partial thickness burns. Cochrane Database of Systematic Reviews2013, Issue 3. Art. No: CD002106. [DOI: 10.1002/14651858.CD002106.pub4]">Wasiak 2013</a>). <a href="./references#CD008058-bbs2-0093" title="WasiakJ , ClelandH , CampbellF , SpinksA . Dressings for superficial and partial thickness burns. Cochrane Database of Systematic Reviews2013, Issue 3. Art. No: CD002106. [DOI: 10.1002/14651858.CD002106.pub4]">Wasiak 2013</a> is a Cochrane Review including 30 RCTs on wound dressing in partial and full thickness burns that found that both the quality of trial reporting and trial conduct were poor. In our review, only facial burns were eligible, resulting in 12 included studies. Several years ago, <a href="./references#CD008058-bbs2-0043" title="DanillaS , WasiakJ , SearleS , ArriagadaC , PedrerosC , ClelandH , et al. Methodological quality of randomised controlled trials in burns care. A systematic review. Burns2009;35(7):956-61.">Danilla 2009</a> investigated the methodological quality of RCTs in burn care. They included 257 eligible studies and concluded that "the reporting standards of RCTs are highly variable and less than optimal in most cases." Furthermore, their results showed an increase in RCTs over time, of increasing size, without a significant improvement in methodological quality. Our review reflects the growing number of RCTs in burn care and also the increasing size of some of these RCTs. However, due to the limited certainty of the evidence, these RCTs contribute only to a limited extent to the knowledge in this field. Initiatives like <a href="./references#CD008058-bbs2-0039" title="BrölmannFE , EskesAM , SumpioBE , MayerDO , MooreZ , AgrenMS , et al. Fundamentals of randomized clinical trials in wound care: reporting standards. Wound Repair and Regeneration2013;21(5):641-7. [DOI: 10.1111/wrr.12087]">Brölmann 2013</a> on guidelines for reporting RCTs will hopefully enhance the standard of reporting in RCTs in wound care. </p> <p><a href="./references#CD008058-bbs2-0093" title="WasiakJ , ClelandH , CampbellF , SpinksA . Dressings for superficial and partial thickness burns. Cochrane Database of Systematic Reviews2013, Issue 3. Art. No: CD002106. [DOI: 10.1002/14651858.CD002106.pub4]">Wasiak 2013</a> concluded: "It is impossible to draw firm and confident conclusions about the effectiveness of specific dressings, however SSD was consistently associated with poorer healing outcomes than biosynthetic, silicon‐coated and silver dressings whilst hydrogel‐treated burns had better healing outcomes than those treated with usual care." At the moment, there is no evidence regarding whether these results apply to facial burns as well. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008058-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008058-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008058-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008058-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical antimicrobial versus non‐antimicrobial agent, Outcome 1: Time to wound healing" data-id="CD008058-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Topical antimicrobial versus non‐antimicrobial agent, Outcome 1: Time to wound healing </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical antimicrobial versus non‐antimicrobial agent, Outcome 2: Time to wound healing: proportion completely healed within 10 days" data-id="CD008058-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Topical antimicrobial versus non‐antimicrobial agent, Outcome 2: Time to wound healing: proportion completely healed within 10 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical antimicrobial versus non‐antimicrobial agent, Outcome 3: Infection" data-id="CD008058-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Topical antimicrobial versus non‐antimicrobial agent, Outcome 3: Infection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical antimicrobial versus non‐antimicrobial agent, Outcome 4: Need for surgery" data-id="CD008058-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Topical antimicrobial versus non‐antimicrobial agent, Outcome 4: Need for surgery </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical antimicrobial versus non‐antimicrobial agent, Outcome 5: Scar quality" data-id="CD008058-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Topical antimicrobial versus non‐antimicrobial agent, Outcome 5: Scar quality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical antimicrobial versus non‐antimicrobial agent, Outcome 6: Patient satisfaction" data-id="CD008058-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Topical antimicrobial versus non‐antimicrobial agent, Outcome 6: Patient satisfaction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 1: Time to wound healing" data-id="CD008058-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 1: Time to wound healing </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 2: Infection" data-id="CD008058-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 2: Infection </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 3: Need for surgery" data-id="CD008058-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 3: Need for surgery </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 4: Need for surgery: mean number" data-id="CD008058-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 4: Need for surgery: mean number </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 5: Scar quality, POSAS, patient reported" data-id="CD008058-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 5: Scar quality, POSAS, patient reported </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 6: Scar quality, POSAS, observer reported" data-id="CD008058-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 6: Scar quality, POSAS, observer reported </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 7: Pain: procedural pain" data-id="CD008058-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 7: Pain: procedural pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 8: Pain: background pain" data-id="CD008058-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 8: Pain: background pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 9: Adverse effects" data-id="CD008058-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 9: Adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 10: Length of hospital stay" data-id="CD008058-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Topical antimicrobial versus alternative antimicrobial agent, Outcome 10: Length of hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 1: Time to wound healing" data-id="CD008058-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 1: Time to wound healing </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 2: Time to wound healing, within patient comparison" data-id="CD008058-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 2: Time to wound healing, within patient comparison </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 3: Infection" data-id="CD008058-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 3: Infection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 4: Scar quality" data-id="CD008058-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 4: Scar quality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 5: Scar quality, within‐patient comparison" data-id="CD008058-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 5: Scar quality, within‐patient comparison </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 6: Pain: procedural pain" data-id="CD008058-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 6: Pain: procedural pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 7: Pain: background pain" data-id="CD008058-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 7: Pain: background pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 8: Pain, within‐patient comparison" data-id="CD008058-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 8: Pain, within‐patient comparison </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 9: Length of hospital stay" data-id="CD008058-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Skin substitute versus topical antibiotic agent, Outcome 9: Length of hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Miscellaneous treatment versus miscellaneous treatment, Outcome 1: Time to wound healing" data-id="CD008058-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Miscellaneous treatment versus miscellaneous treatment, Outcome 1: Time to wound healing </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Miscellaneous treatment versus miscellaneous treatment, Outcome 2: Time to wound healing: number completely healed in 14 days" data-id="CD008058-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Miscellaneous treatment versus miscellaneous treatment, Outcome 2: Time to wound healing: number completely healed in 14 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Miscellaneous treatment versus miscellaneous treatment, Outcome 3: Infection" data-id="CD008058-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Miscellaneous treatment versus miscellaneous treatment, Outcome 3: Infection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Miscellaneous treatment versus miscellaneous treatment, Outcome 4: Scar quality" data-id="CD008058-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Miscellaneous treatment versus miscellaneous treatment, Outcome 4: Scar quality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Miscellaneous treatment versus miscellaneous treatment, Outcome 5: Pain" data-id="CD008058-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Miscellaneous treatment versus miscellaneous treatment, Outcome 5: Pain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008058-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/urn:x-wiley:14651858:media:CD008058:CD008058-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Miscellaneous treatment versus miscellaneous treatment, Outcome 6: Patient satisfaction" data-id="CD008058-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_t/tCD008058-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Miscellaneous treatment versus miscellaneous treatment, Outcome 6: Patient satisfaction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/media/CDSR/CD008058/image_n/nCD008058-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008058-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Topical antimicrobial agent compared with topical non‐antimicrobial agent for facial burns</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p><b>Topical antimicrobial agent compared with topical non‐antimicrobial agent for facial burns</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with facial burns </p> <p><b>Setting:</b> burn centres </p> <p><b>Intervention:</b> topical antimicrobial agent </p> <p><b>Comparison:</b> topical non‐antimicrobial agent </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> <p><b>(follow‐up)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with topical non‐antimicrobial agent</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with topical antimicrobial agent</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Time to complete wound healing</b> (time to event data) </p> <p>(6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported HR (adjusted for total body surface area burned) was 0.84 (0.78 to 1.85) (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Facial burns treated with SSD probably have a similar time to complete wound healing, compared with MEBO. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete wound healing</b> (days) </p> <p>(until wound healing)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean time to wound healing 10.35 (SD 2.8) and 12.05 (SD 2.4) (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean time to wound healing</p> <p>10.05 (SD 2.3) (<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in time to wound healing between topical anti‐microbial agents (Aquacel‐Ag) and non‐antimicrobial agents (MEBO) and saline‐soaked dressings) in facial burns. </p> <p>Data from <a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a> not used, it was not stated or verifiable that all participants healed during the study. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of wounds completely healed within 10 days</b> </p> <p><b>(10 days)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.68 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>39<br/>(<a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <b><sup>c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There may be little or no difference in the proportion of wounds completely healed within 10 days between SSD and MEBO. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>824 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>774 per 1000<br/>(560 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Change in wound surface area over time or partial healing</b> – not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies measured change in wound surface area over time or partial wound healing.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Infection</b> </p> <p>(unclear follow‐up<b>)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.38<br/>(0.12 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>40<br/>(<a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether Aquacel Ag increases or reduces the risk of infection compared with MEBO in facial burns as evidence is of very low certainty. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 per 1000<br/>(48 to 484) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MEBO:</b> Moist Exposed Burn Ointment; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>SSD:</b> silver sulphadiazine. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for imprecision: limited number of participants (fewer than 100). </p> <p><sup>b</sup>Downgraded once for unclear selection bias, performance and detection bias: unclear random sequence generation and allocation concealment, lack of blinding participants and providers, unclear blinding outcome assessment. Downgraded once for imprecision: effect estimates could not be calculated, limited number of participants (fewer than 100).<br/><sup>c</sup>Downgraded twice for imprecision: substantial number of events in small number of people (31 events in 39 participants), and a 95% CI including both a substantial (&gt;25%) increase and decrease.<br/><sup>d</sup>Downgraded once for unclear selection bias, performance bias and detection bias, unclear attrition bias: unclear random sequence generation and allocation concealment, lack of blinding participants and providers, unclear blinding outcome assessor, unclear completeness outcome data. Downgraded twice for imprecision: very limited number of events in small‐sized study (11 in 40 participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Topical antimicrobial agent compared with topical non‐antimicrobial agent for facial burns</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008058-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical antimicrobial compared with alternative antimicrobial agent for facial burns</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Topical antimicrobial compared with alternative antimicrobial agent for facial burns</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with facial burns </p> <p><b>Setting:</b> burn centres </p> <p><b>Intervention:</b> topical antimicrobial </p> <p><b>Comparison:</b> alternative antimicrobial agent </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> <p><b>(follow‐up)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with alternative antimicrobial agent</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with topical antimicrobial</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete wound healing</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies measured time to complete wound healing.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of wounds completely healed</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No studies measured proportion of wounds completely healed.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in wound surface area over time or partial healing (&gt; 95%)</b> </p> <p>(12 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to wound healing was 21.4 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD 7.10 days lowe<b>r</b><br/>(16.43 lower to 2.23 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 (<a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference in time to wound healing between SSD and cerium‐SSD in facial burns. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Infection</b> </p> <p>(until wound healing)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.73<br/>(0.46 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15<br/>(<a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether mafenide acetate cream and gentamicin differs from mafenide acetate only in the risk of infection in facial burns as evidence is of very low certainty. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>365 per 1000<br/>(230 to 585) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SSD:</b> silver sulphadiazine. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for imprecision: one study with 142 participants, optimal information size not reached. Downgraded once for high risk on performance bias and detection bias, and attrition bias not related to the outcome: lack of blinding participants, providers, and outcome assessor.<br/><sup>b</sup>Downgraded twice for high risk on performance bias, detection bias and reporting bias; and unclear selection and attrition bias; lack of blinding participants, providers, unclear blinding outcome assessor, and reporting bias assessor, in combination with unclear random sequence allocation and concealment. allocation. Also downgraded twice for imprecision: one small‐sized study (15 participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical antimicrobial compared with alternative antimicrobial agent for facial burns</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008058-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Skin substitute compared with topical antimicrobial agent for facial burns</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Skin substitute compared with topical antibiotic agent for facial burns</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with facial burns </p> <p><b>Setting:</b> burn centres </p> <p><b>Intervention:</b> skin substitute </p> <p><b>Comparison:</b> topical antibiotic agent </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> <p><b>(follow‐up)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with topical antibiotic agent</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with skin substitute</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete wound healing</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies measured time to complete wound healing.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of wounds completely healed</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No studies measured proportion of wounds completely healed.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in wound surface area over time or partial wound healing (&gt; 90%)</b> </p> <p>(until wound healing)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to wound healing was 15 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6 days lower<br/>(8.69 lower to 3.31 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/>(<a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A bioengineered skin substitute (TransCyte) might decrease time to 90% wound healing in facial burns, compared to a non‐specified antimicrobial agent. Data from <a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>, <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>, and <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> not used because of concern of overlapping populations, lack of estimate of variance and comparison of wounds within participants. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Infection</b> </p> <p>(until wound healing and unclear (2x))</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>56<br/>(<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a>; <a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether skin substitutes increase or reduce the risk of infection compared with the use of topical antimicrobial agents in facial burns as evidence is of very low certainty. No events reported in 2 RCTs (<a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a>; <a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a> (control group not reported)), third RCT reported 4 events in 50 wounds in 25 participants (<a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a>). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for risk of bias: unclear selection bias, high risk on performance bias and detection bias: unclear random sequence generation and allocation concealment, lack of blinding participants, providers and outcome assessor. Downgraded once for imprecision: one small‐sized study (34 participants).<br/><sup>b</sup>Downgraded once for risk of bias: unclear selection bias, high risk on performance bias and detection bias: unclear random sequence generation and allocation concealment, lack of blinding patients, providers and outcome assessor. Downgraded twice for imprecision: no (report of) events in two small‐sized studies (44 participants), unclear data in third RCT. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Skin substitute compared with topical antimicrobial agent for facial burns</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008058-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Miscellaneous treatment compared with miscellaneous treatment for facial burns</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Miscellaneous treatment compared with miscellaneous treatment for facial burns</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with facial burns </p> <p><b>Setting:</b> burn centres </p> <p><b>Intervention:</b> miscellaneous treatment (for details see comments) </p> <p><b>Comparison:</b> miscellaneous treatment (for details see comments) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> <p><b>(follow‐up)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with miscellaneous treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with miscellaneous treatment</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to complete wound healing</b> </p> <p>(until wound healing)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to complete wound healing was 12.05 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.7 days lower<br/>(3.32 lower to 0.08 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(<a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MEBO may slightly reduce mean time to wound healing in facial burns compared with saline‐soaked dressing. </p> <p>Data from <a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a> not used, it was not stated or verifiable that all participants healed during the study. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of wounds completely healed in 14 days</b> </p> <p>(14 days)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.77<br/>(1.87 to 12.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43<br/>(<a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A cream containing Helix Aspersa (Elicina) may slightly increase the proportion completely healed at 14 days in facial burns, compared with MEBO. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>894 per 1000<br/>(351 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in wound surface area over time or partial wound healing</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a> measured change in wound surface area over time, data not reported. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Infection</b> </p> <p>(follow‐up unclear)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43<br/>(<a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether a cream containing Helix Aspersa (Elicina) increases or reduces the risk of infection compared with use of MEBO in facial burns as evidence is of very low certainty. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>MEBO:</b> Moist Exposed Burn Ointment; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for risk of bias due to unclear selection bias, high risk on performance bias and detection bias: unclear random sequence generation and allocation concealment, lack of blinding participants and providers, and unclear blinding outcome assessor. Downgraded once for imprecision: one small‐sized study (40 participants).<br/><sup>b</sup>Downgraded once for risk of bias due to high risk selection bias, performance bias and detection bias. No allocation concealment, lack of blinding providers, unclear blinding outcome assessor unclear similarity at baseline. Downgraded once for imprecision: one small‐sized study (43 participants).<br/><sup>c</sup>Downgraded once for risk of bias due to high risk selection bias, performance bias and detection bias: no allocation concealment, lack of blinding providers, unclear blinding outcome assessor unclear similarity at baseline. Downgraded twice for very serious imprecision: no events in one small‐sized study (43 participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Miscellaneous treatment compared with miscellaneous treatment for facial burns</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008058-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of studies for comparisons: interventions and primary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time to wound healing</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in wound surface area, proportion of wound partly healed</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Complete healing data reported?</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Infection</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Topical antimicrobial agent compared with topical non‐antimicrobial agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SSD vs</p> <p>MEBO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to event analysis, days to complete wound healing; number of participants healed at 10 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver hydrocolloid dressing (Aquacel Ag) vs MEBO vs saline‐soaked dressings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver hydrocolloid dressing (Aquacel Ag) vs MEBO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated nor verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported,<br/>not prespecified, no definition </p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Topical antimicrobial agents compared with other topical antimicrobial agents</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mafenide acetate cream + gentamicin via iontophoresis (7 participants) vs usual care (mafenide acetate cream) (8 participants) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical features</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerium‐SSD vs SSD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to event anaysis, days to 90% wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Skin substitutes compared with topical antimicrobial agents</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biological skin substitute coated with fibronectin (TransCyte) vs Bacitracin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to 95% wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical features</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bioactive skin substitute (a bilayered, biologically active, temporary skin substitute (TransCyte)) vs antibacterial ointment, not specified </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to 90% wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycerolised allograft cadaver (corpse) skin vs SSD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months (maximum)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported in 1 group, not prespecified, no definition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biological dressing (porcine Xenoderm) vs Physiotulle Ag (Coloplast)</p> <p>50 wounds in 25 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months (scar)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to 95% wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical features</p> </td> </tr> <tr> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Miscellaneous treatment compared with miscellaneous treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MEBO vs saline‐soaked dressing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rhGM‐CSF hydrogel (1 μg/cm<sup>2</sup>/day) vs placebo hydrogel (matrix hydrogel) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% wound healing at 3, 5, 7 and 14 days after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enzymatic debridement (collagenase) vs antimicrobial agent (Bacitracin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a><a href="https://archie.cochrane.org/sections/documents/view?version=z1901161709573099519576834183040&amp;format=REVMAN#STD-NCT01668030" target="_blank">0</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wound epithelialisation: time to establish a wound bed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, verifiable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Documented wound or blood infection confirmed by a positive laboratory result.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cream containing Helix Aspersa extract (terrestrial brown snail secretions extract (Elicina) vs MEBO </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years (scar)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days to complete wound healing, number of participants healed at 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated or verifiable (days to complete wound healing)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Burn swab cultures; systemic infections,<br/>not prespecified </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>MEBO: Moist Exposed Burn Ointment; rhGM‐CSF: recombinant human granulocyte‐macrophage colony‐stimulating factor; SSD: silver sulphadiazine. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of studies for comparisons: interventions and primary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008058-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of studies for comparisons: interventions and secondary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Scar quality</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Patient satisfaction</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse effect</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>QoL</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>LOS</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="top"> <p><b>Topical antimicrobial agent compared with topical non‐antimicrobial agent</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SSD vs MEBO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reconstructive surgery, following wound closure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver hydrocolloid dressing (Aquacel Ag) vs MEBO vs saline‐soaked dressings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until</p> <p>wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of healing (4‐point scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐point scale (excellent‐ poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver hydrocolloid dressing (Aquacel Ag) vs MEBO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vancouver Scar Scale, incidence hypertrophic scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐point scale: (comfortable‐discomfortable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="top"> <p><b>Topical antimicrobial agents compared with other topical antimicrobial agents</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mafenide acetate cream and gentamicin via iontophoresis (7 participants) vs usual care (mafenide acetate cream) (8 participants) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery, following treatment by topical agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerium‐SSD vs SSD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery, following treatment by topical agent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>POSAS, colour (dermaspectometer), elasticity (cutometer), functional and anatomical impairments </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAT (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="top"> <p><b>Skin substitutes compared with topical antimicrobial agents</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biological skin substitute coated with fibronectin (TransCyte) vs Bacitracin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LOS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bioactive skin substitute (a bilayered, biologically active, temporary skin substitute (TransCyte)) vs antibacterial ointment, not specified </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycerolised allograft cadaver (corpse) skin vs SSD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months (maximum)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Biological dressing (porcine Xenoderm) vs Physiotulle Ag (Coloplast)</p> <p>50 wounds in 25 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months (scar)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vancouver Scar Scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="top"> <p><b>Miscellaneous treatment compared with miscellaneous treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MEBO vs saline‐soaked dressing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until wound healing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of healing (4‐point scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enzymatic debridement (Collagenase) vs antimicrobial agent (Bacitracin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>POSAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (0–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality, serious adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cream containing Helix Aspersa extract (Elicina) vs MEBO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 years (scar)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS (1–10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>LOS: length of hospital stay; MEBO: Moist Exposed Burn Ointment; POSAS: Patient and Observer Scar Assessment Scale; QoL: quality of life; SSD: silver sulphadiazine; VAS: visual analogue scale. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of studies for comparisons: interventions and secondary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008058-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results from included trials</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main baseline characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants and dropout rate</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Primary outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Secondary outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0001" title="AngES , LeeST , GanCS , SeeP , ChanYH , NgLH , et al. The role of alternative therapy in the management of partial thickness burns of the face - experience with the use of Moist Exposed Burn Ointment (MEBO) compared with silver sulphadiazine. Annals of the Academy of Medicine2000;29(1):7-10. ">Ang 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants:</p> <p>I: 22; C: 17.</p> <p>% TBSA burned (mean):</p> <p>I: 1.56 (SE 0.18; range 0.5–3.5).</p> <p>C: 2.16 (SE 0.38; range 0.13–6.0).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 115.</p> <p>After randomisation: I: 58; C: 57.</p> <p>Dropouts: I: 0; C:3.</p> <p>Participants with facial burns: I: 22; C:17.</p> <p>Participants in short‐term analysis:</p> <p>I: 22; C:17.</p> <p>Participants in long‐term analysis (6 months):</p> <p>I: 20; C:17.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing (number of days taken for face‐wound to heal):</p> <p>I: not reported; C: 2–35 days (range).</p> <p>Proportion completely healed in 10 days:</p> <p>I: 17/22; C: 14/17.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for surgery (need for reconstructive surgery 6 months PB):</p> <p>I: 0/20; C: 0/17.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0002" title="DemlingRH , DeSantiL . Management of partial thickness facial burns (comparison of topical antibiotics and bio-engineered skin substitutes). Burns1999;25(3):256-61. ">Demling 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants:</p> <p><i>Minor burns:</i> I: 5; C: 5.<br/><i>Major burns:</i> I: 5; C: 6. </p> <p>Mean age:</p> <p><i>Minor burns:</i> I: 31 (SD 8) years; C: 29 (SD 7) years<i>.</i> <br/><i>Major burns:</i> I: 44 (SD 10) years; C: 40 (SD 8 years)<i>.</i> </p> <p>Aetiology: flame.</p> <p>% TBSA burned (mean):</p> <p><i>Minor burns:</i> I: 10 (SD 3); C: 7 (SD 2)<i>.</i> <br/><i>Major burns:</i> I: 32 (SD 9); C: 30 (SD 8)<i>.</i> </p> <p>% TBSA burned full‐thickness (mean):</p> <p><i>Minor burns:</i> I: 0; C: 0<i>.</i> <br/><i>Major burns:</i> I: 10 (SD 3); C: 8 (SD 2)<i>.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 21.</p> <p>Number of participants with minor burns: 10.</p> <p>Number of participants with major burns: 11.</p> <p>After randomisation:</p> <p><i>Minor burns:</i> I: 5; C: 5<i>.</i> <br/><i>Major burns:</i> I: 5; C: 6<i>.</i> </p> <p>Participants in short‐term analysis:</p> <p><i>Minor burns:</i> I: 5; C: 5<i>.</i> <br/><i>Major burns:</i> I: 5; C: 6<i>.</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to partial wound healing</p> <p>(mean number of days to &gt; 90% re‐epithelialisation):</p> <p><i>Minor burns:</i> I: 8 (SD 1); C: 12 (SD 3); reported P &lt; 0.05. </p> <p><i>Major burns:</i> I: 8 (SD 2); C: 14 (SD 4); reported P &lt; 0.05. </p> <p>Wound infection (signs of local wound infection):</p> <p><i>Minor burns:</i> I: 0; C: 0.<br/><i>Major burns:</i> I: 0; C: 0. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain (procedural pain, during facial care (mean):</p> <p><i>Minor burns:</i> I: 2 (SD 1); C: 5 (SD 1).<br/><i>Major burns:</i> I: 2 (SD 1); C: 5 (SD 1). </p> <p>Pain (background pain, between facial care) (mean):</p> <p><i>Minor burns:</i> I: 1 (SD 0.5); C: 3 (SD 2).<br/><i>Major burns:</i> I: 2 (SD 1); C: 4 (SD 2). </p> <p>Length of stay (mean):</p> <p><i>Minor burns:</i> I: 1 (SD 0.5); C: 3 (SD 1).<br/><i>Major burns:</i> not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0003" title="DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Ostomy/Wound Management2002;48(8):52. DemlingRH , DeSantiL . Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome. Wounds2002;14(6):230-4. ">Demling 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I: 16; C: 18.</p> <p>Mean age: I: 39 (SD 9); C: 40 (SD 8).</p> <p>Aetiology:</p> <p><i>Flame:</i> I: 11; C: 12<i>.</i> <br/><i>Scald:</i> I: 5; C: 6. </p> <p>% TBSA burned (mean): I: 24 (SD 8); C: 21 (SD 9).</p> <p>% TBSA burned full‐thickness (mean): I: 12 (SD 7); C: 10 (SD 6).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 34.</p> <p>After randomisation:</p> <p>I: 16; C: 18.</p> <p>Participants in short‐term analysis:</p> <p>I: 16; C: 18.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to partial wound healing (mean number of days to &gt; 95% re‐epithelialisation:</p> <p>I: 9 (SD 4); C: 15 (SD 4); reported P &lt; 0.05.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain (procedural pain, during facial care) (mean): I: 3 (SD 1); C: 7 (SD 2).</p> <p>Pain (background pain, between facial care) (mean): I: 2 (SD 1); C: 4 (SD 2).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0004" title="DesaiMH , RutanRL , HeggersJP , AlvaradoMI , McElroyK , HerndonDN . The role of gentamicin iontophoresis in the treatment of burned ears. Journal of Burn Care and Rehabilitation1991;12(6):521-4. ">Desai 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I: 7; C: 8.</p> <p>Mean age: I: 11.4 (SE 1.2); C: 9.5 (SE 1.6).</p> <p>% TBSA burned (mean): I: 35 (SE 7); C: 50 (SE 6).</p> <p>% TBSA burned full‐thickness (mean): I: 20 (SE 9); C: 32 (SE 7).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 15.</p> <p>After randomisation: I: 7; C: 8.</p> <p>Participants in short‐term analysis: I: 7; C: 8.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wound infection (occurrence of chondritis): I: 3; C: 4.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for surgery (mean number of surgical procedures): I: 1.2 (SE 0.1) C: 1.0 (SE 0); reported P &lt; 0.05. </p> <p>Adverse effects (occurrence of gentamicin‐resistant micro‐organisms): I: 29%; C: 0%<i>.</i> </p> <p>Length of stay (mean): I: 26 (SE 1); C: 38 (SE 3).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0005" title="HindyA . Comparative study between sodium carboxymethyl-cellulose silver, moist exposed burn ointment, and saline-soaked dressing for treatment of facial burns. Annals of Burns and Fire Disasters2009;22(3):131-7. ">Hindy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I: 20; C1; 20; C2: 20.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 60.</p> <p>After randomisation: I: 20; C1: 20; C2: 20.</p> <p>Participants in short‐term analysis: I: 20; C1: 20; C2: 20.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing (mean): I: 10.05 (SD 2.3); C1: 10.35 (SD 2.8); C2: 12.05 (SD 2.4), reported P &lt; 0.05. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain: (mean) day 1 and 2: C1: 3.1 (SD 1.9); day 3 onwards: C1: 1.3 (SD 1.5), I and C2 not presented, least pain in C1, reported P &lt; 0.05). </p> <p>Scar quality (quality of healing): excellent: I: 16; C1: 16; C2: 11, reported P &gt; 0.05. </p> <p>Patient satisfaction: excellent: I: 11; C1: 12; C2: 2, reported P &lt; 0.05.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0006" title="HorchRE , JeschkeMG , SpilkerG , HerndonDN , KoppJ . Treatment of second degree facial burns with allografts: preliminary results. Burns2005;31(5):597-602. [DOI: 10.1016/j.burns.2005.01.011]">Horch 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I: 5; C; 5.</p> <p>Median age I+C: 34.3 (range 24–67) years.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 10.</p> <p>After randomisation: I: 5; C: 5.</p> <p>Participants in short‐term analysis: I: 5; C:5.</p> <p>Participants in long‐term analysis: I: 5; C:5.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing (median)</p> <p>I: 10.5; C: 12.4, reported P &lt; 0.05.</p> <p>Wound infection (signs of underlying infection) I: 0; C: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scar quality (scar formation, maximum 6 months): I: 0; C: 2.</p> <p>Adverse effects (localised partial integration of the biological dressing) I: 1; C: 0. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0007" title="JiaaoY , KaiS , HuaJZ , ChunZJ , HaiNZ , JingLH , et al. Treatment of deep second-degree burn in pediatric population with recombinant human GM-CSF hydrogel. Wound Repair and Regeneration2011;19(2):A29. ">Jiaao 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I+C: 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 30.</p> <p>After randomisation: ?</p> <p>Participants in short‐term analysis: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing</p> <p>(mean): I: 13.47 (SD 1.08) days; C: 18.69 (SD 2.35) days, reported P &lt; 0.01</p> <p>Change in wound surface area over time: percentage of healing at 3, 5, 7 and 14 days after treatment, reported P &lt; 0.01 at day 5, 7 and 14 days after treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0008" title="LehnaCR . Comparison of wound bed establishment in facial burns. clinicaltrials.gov/ct2/show/results/NCT01668030 (first registered 8 August 2012). ">Lehna 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: 10 (within patient comparison).</p> <p>Age: 9 participants aged 18–64 years, 1 participant aged ≥ 65 years.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 10.</p> <p>After randomisation: 10.</p> <p>Participants in short‐term analysis: 10.</p> <p>Participants in long‐term analysis: no data provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing (days to complete epithelialisation, mean): I1: 37.6; I2: 37.4, reported P = 0.0853. </p> <p>Wound infection: not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain: not reported.</p> <p>Scar quality: not reported.</p> <p>Adverse effects: all‐cause mortality: 1.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0009" title="MabroukA , BoughdadiNS , HelalHA , ZakiBM , MaherA . Moist occlusive dressing (Aquacel Ag) versus moist open dressing (MEBO) in the management of partial-thickness facial burns: a comparative study in Ain Shams University. Burns2012;38(3):396-403. ">Mabrouk 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I1 (Aquacel Ag): 20; I2 (MEBO): 20.</p> <p>Mean age: I1: 41.4 years, I2: 37.5 years.</p> <p>Total TBSA range: I: 5–30, C: 7–30.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 40.</p> <p>After randomisation: I1: 20; I2: 20.</p> <p>Participants in short‐term analysis: I1: 20; I2: 20.</p> <p>Participants in long‐term analysis (3, 6 months), I1: 7–10; I2: 10–14 (table 3).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing (mean)</p> <p>I1: 10.5 days; I2: 12.4 days, reported P &lt; 0.05.</p> <p>Wound infection (rate)</p> <p>I1: 3/20; I2: 8/20.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain (mean): I1: 4.1; I2: 4.6.</p> <p>Scar quality (Vancouver Scar Scale): I1: 4; I2: 7, reported P &gt; 0.05.</p> <p>Patient satisfaction (comfortable, mild discomfort, discomfort): I1: 14, 2, 4; I2: 10, 4, 6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0010" title="OenIM , Van BaarME , MiddelkoopE , NieuwenhuisMK , Facial Burns Group. Effectiveness of cerium nitrate-silver sulfadiazine in the treatment of facial burns: a multicenter, randomized, controlled trial. Plastic and Reconstructive Surgery2012;130(2):274-83e. ">Oen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: I1: 78; I2: 76.</p> <p>Mean age: I: 41.9 (SD 16.9) years; I2: 41.3 (SD 14.5) years.</p> <p>Aetiology:</p> <p><i>Flame:</i> I1: 70; I2: 60<i>.</i> <br/><i>Scald:</i> I1: 4; I2: 3. </p> <p>% TBSA burned (median (IQR): I1: 9.8 (5.0–19.4); I2: 9.3 (4.5–17.0).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 179.</p> <p>After randomisation: I1: 90; I2: 89.</p> <p>After postrandomisation exclusion: I1: 78; I2: 76.</p> <p>Participants in short‐term analysis (primary analysis): I1: 77; I2: 73.</p> <p>Participants in long‐term analysis (6 months) I1: 60; I2: 50)</p> <p>(12 months): I1: 50; I2: 46.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to wound partial healing: (survival analysis, all participants), reported P = 0.71. </p> <p>Median days (25–75th percentile) to healing (&gt; 90%) in wounds without surgery: I1: 11.0 (7.0–15.0); I2: 9.0 (5.0–17.75), reported P = 0.17. </p> <p>Mean time to wound healing: I1: 14.3 (SD 14.5) days; I2: 21.4 (SD 37.6) days (data delivered upon request). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for surgery: I1: 13/77; I2: 15/73, reported P = 0.565, OR 0.8 (95% CI 0.3 to 1.8). </p> <p>Pain (background pain, before wound care, mean): I1: 0.6 (SEM 0.2); I2: 1.2 (SEM 0.4), reported P = 0.16. </p> <p>Pain (procedural pain, during wound care): I1: 1.3 (SEM 0.3); I2: 1.6 (SEM 0.5), reported P = 0.59. </p> <p>Scar quality at 12 months (Patient and Observer Scar Assessment Scale) (median):</p> <p>(patient report): I1: 1.2 (25–75th percentile 1.0–2.2); I2: 1.0 (25–75th percentile 1.0–1.8), reported P = 0.42; </p> <p>(observer report): I1: 1.4 (25–75th percentile 1.2–1.8); I2: 1.4 (25–75th percentile 1.2–1.6), reported P = 0.17. </p> <p>(mean):</p> <p>(patient report) I1: 2.0 (SD 1.5); I2: 1.8 (SD 1.5);</p> <p>(observer report) I1: 1.7 (SD 0.9); I2: 1.6 (SD 0.8) (delivered upon request).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0011" title="TsoutsosD , KakagiaD , TamparopoulosK . The efficacy of Helix aspersa Müller extract in the healing of partial thickness burns: a novel treatment for open burn management protocols. Journal of Dermatological Treatment2009;20:219-22. ">Tsoutsos 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants I: 27; C: 16.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 46.</p> <p>After randomisation: I: 27; C: 19, after postrandomisation exclusion: I: 27; C: 16.</p> <p>Participants in short‐term analysis: not documented.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to complete wound healing (mean days: I: 11 (SD 2); C: 15 (SD 3), reported P &lt; 0.0001. </p> <p>Number of participants with complete wound healing within 14 days: I: 27/27; C: 3/16, P value not reported. </p> <p>Wound infection: bacterial colonisation in all participants; absence of signs of systemic infection. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain (mean pain reduction scores): I: 2.7 (SD 1.35); C: 2.00 (SD 0.89), reported P interaction intervention by change pain = 0.072. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008058-bbs2-0012" title="WangQ , Liu X-W, Lv R-R, HuoR . Biological dressing A versus Physiotulle Ag in the repair of degree ll facial burns. Chinese Journal of Tissue Engineering Research2015;19:2573-7. [DOI: 10.3969/j.issn.2095-4344.2015.16.021]">Wang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants: 25 (within‐patient comparison): 15 superficial degree II burns; 10 deep degree II burns. </p> <p>% TBSA burned (mean): 45.1 (SD 25.2) (superficial degree II burns); 54.9 (SD 31.7) (deep degree II burns). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Initial number of participants: 25.</p> <p>After randomisation: 25.</p> <p>Participants in short‐term analysis: 25.</p> <p>Participants in long‐term analysis: no numbers provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to wound healing (mean days)</p> <p>Superficial degree II burns: I: 8.6 (SD 1.12); C: 8.67 (SD 1.18) (reported P = 0.855).</p> <p>Deep degree II burns: I: 15.80 (SD 1.55); C: 18.20 (SD 1.55), reported P = 0.005.</p> <p>Infection:</p> <p>Superficial degree II burns:</p> <p>I: 1/15; C: 1/15, P &gt; 0.05</p> <p>Deep degree II burns:</p> <p>I: 1/10; C: 1/10, reported P &gt; 0.05.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain (mean VAS)</p> <p>Superficial degree II burns:</p> <p>I: 2.73 (SD 0.70); C: 1.53 (SD 0.83), reported P = 0.000.</p> <p>Deep degree II burns:</p> <p>I: 5.70 (SD 0.95); C: 2.70 (SD 0.48), reported P = 0.000.</p> <p>Scar quality at 3 months (mean Vancouver Scar Scale)</p> <p>Superficial degree II burns:</p> <p>I: 0.80 (SD 0.77); C: 0.80 (SD 0.77), reported P = 1.000.</p> <p>Deep degree II burns: I: 3.50 (SD 0.71); C: 5.50 (SD 1.08), reported P = 0.000.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>C: comparator; CI: confidence interval; I: intervention; IQR: interquartile range; MEBO: Moist Exposed Burn Ointment; OR: odds ratio; PB: postburn; SD: standard deviation; SE: standard error; SEM: standard error of the mean; TBSA: total body surface area. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results from included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/full#CD008058-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008058-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical antimicrobial versus non‐antimicrobial agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Time to wound healing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Time to wound healing: proportion completely healed within 10 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.68, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.12, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Need for surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Scar quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.87, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Patient satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.06, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical antimicrobial versus non‐antimicrobial agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008058-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical antimicrobial versus alternative antimicrobial agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Time to wound healing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.10 [‐16.43, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.29, 2.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Need for surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.42, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Need for surgery: mean number <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Scar quality, POSAS, patient reported <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.40, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Scar quality, POSAS, observer reported <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.24, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Pain: procedural pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.44, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Pain: background pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.48, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.62 [0.31, 100.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Length of hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.00 [‐18.20, ‐5.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical antimicrobial versus alternative antimicrobial agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008058-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Skin substitute versus topical antibiotic agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Time to wound healing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.00 [‐8.69, ‐3.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Time to wound healing, within patient comparison <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Scar quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Scar quality, within‐patient comparison <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Pain: procedural pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Pain: background pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Pain, within‐patient comparison <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Length of hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐2.98, ‐1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Skin substitute versus topical antibiotic agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008058-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Miscellaneous treatment versus miscellaneous treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Time to wound healing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Time to wound healing: number completely healed in 14 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.77 [1.87, 12.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Scar quality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.92, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.03, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Patient satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [1.54, 23.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Miscellaneous treatment versus miscellaneous treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008058.pub3/references#CD008058-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008058.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008058-note-0020">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008058-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008058-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008058-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD008058-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008058-note-0019">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD008058-note-0013">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD008058-note-0014">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008058-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008058-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008058\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008058\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008058\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008058\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008058\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008058.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008058.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008058.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008058.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008058.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717319643"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008058.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717319647"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008058.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db5080e539365',t:'MTc0MDcxNzMyMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 